Title: Induction of selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir

Authors: Shringar Rao¹, Cynthia Lungu², Raquel Crespo¹, Thijs H. Steijaert¹, Alicja Gorska¹, Robert-Jan Palstra¹, Henrieke A. B. Prins³, Wilfred van Ijcken⁴, Yvonne M. Mueller⁵, Jeroen J. A. van Kampen², Annelies Verbon³, Peter D. Katsikis⁵, Charles A. B. Boucher², Casper Rokx³, Rob A. Gruters², Tokameh Mahmoudi^{1*}

Affiliations:

¹Department of Biochemistry, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.

²Department of Viroscience, Erasmus Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands.

³Department of Internal Medicine, section of Infectious Diseases, Erasmus University Medical Center, Rg-530, PO Box 2040 3000CA Rotterdam, The Netherlands.

⁴Erasmus Center for Biomix, Erasmus University Medical Center, Ee-671, PO Box 2040, 3000CA Rotterdam, Netherlands.

⁵Department of Immunology, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.

*To whom correspondence should be addressed: t.mahmoudi@erasmusmc.nl.

ABSTRACT

An innovative approach to eliminate HIV-1-infected cells emerging out of latency, the major hurdle to HIV-1 cure, is to pharmacologically reactivate viral expression and concomitantly trigger intracellular pro-apoptotic pathways in order to selectively induce cell death (ICD) of infected cells, without reliance on the extracellular immune system. In this work we demonstrate the effect of DEAD-box polypeptide 3, X-Linked (DDX3) inhibitors on selectively inducing cell death in latent HIV-1-infected cell lines, primary CD4+ T cells and in CD4+ T cells from cART-suppressed people living with HIV-1 (PLWHIV). RNA sequencing analysis revealed that while overall gene expression was minimally dysregulated, DDX3 inhibition in independent donor CD4+ T cells led to significant downregulation of BIRC5 and HSPB1A, genes critical to cell survival during HIV-1 infection. We used single-cell FISH-Flow technology to characterise latency reversal and the contribution of viral RNA to inducing cell death; pharmacological targeting of DDX3 induced HIV-1 RNA expression, resulting in phosphorylation of IRF3, upregulation of IFN β and selective induction of apoptosis in viral RNA-expressing CD4+ T cells from PLWHIV but not bystander cells. DDX3 inhibitor treatment of CD4+ T cells from PLWHIV in an *in vitro* culture model over five days resulted in an approximately 50% reduction of the inducible latent HIV-1 reservoir as determined by quantitation of CA HIV-1 RNA, by TILDA, as well as by FISH-Flow technology. Our data support the translation of DDX3 inhibitor class compounds into HIV-1 curative strategies and provide proof of concept for pharmacological reversal of latency coupled to induction of apoptosis towards elimination of the inducible reservoir.

INTRODUCTION

The main obstacle towards a Human Immunodeficiency Virus Type-1 (HIV-1) cure is the presence of a latent viral reservoir that does not actively produce viral particles, but retains the ability to do so and is not eliminated by combination antiretroviral therapy (cART)^{1,2}. One strategy to eliminate the latent HIV-1 reservoir is the ‘Shock and Kill’ approach that involves the use of ‘latency reversing agents’ (LRAs) to reactivate viral gene expression (Shock), followed by elimination of the cells harbouring reactivated provirus (Kill)³. The ‘Kill’ aspect of this approach has largely depended on an effective host adaptive immune response. Although clinical studies with LRAs demonstrated induced reactivation *in vivo*, limited to no reduction in the size of the viral reservoir or time to viral rebound post cessation of cART was observed, indicating that elimination of reactivating cells warrants more attention⁴⁻⁶. So far, broadly neutralising antibodies, therapeutic vaccines, chimeric antigen receptors, checkpoint inhibitors and engineered bispecific antibodies have been investigated to eliminate reactivated HIV-1-infected cells (reviewed in⁷). However, dependency on cell-mediated and humoral immune responses that are already compromised in HIV-infected individuals because of impaired CD4+ T cell help and exhausted immune compartments poses a considerable obstacle to these strategies. Indeed, early results from combinatorial clinical trials which combine LRAs and immune-enhancing clearance strategies demonstrated that although HIV-1-specific immune responses were induced, no decrease in the size of viral reservoir or viral control in the absence of cART were observed (⁸⁻¹⁰, reviewed in¹¹).

A parallel approach to eliminate the viral reservoir independently of the extracellular immune system is to pharmacologically trigger pathways that intrinsically induce cell death (ICD) in reactivating HIV-1-infected reservoir cells. For example, using compounds to activate innate intracellular signalling pathways could trigger apoptosis. Several HIV-1 proteins have been

demonstrated to have both anti-apoptotic activity in the early stages of the viral replication cycle and pro-apoptotic activity in the later replication stages¹². By inhibiting viral anti-apoptotic activity or by promoting pro-apoptotic functions, HIV-1-infected cells can be selectively eliminated, leading to a reduction in the size of the viral reservoir. Multiple pro-apoptotic compounds that have been developed in context of cancer research could potentially be repurposed for viral reservoir elimination and some have been investigated for their ability to induce cell death of HIV-1-infected cells (reviewed in^{13,14}). Interestingly, an important characteristic of the latent viral reservoir that has recently come to light is that while it is transcriptionally competent, it does not necessarily generate viral proteins due to post-transcriptional blocks^{15,16}. Induced viral RNA does however retain the ability to trigger innate antiviral signalling pathways^{17,18} and possibly induce cell death in reactivating cells. The potential contribution of inducing viral transcription as a strategy to induce death of the infected cells has been thus far under-investigated¹⁹.

Advanced single-cell fluorescence in situ hybridisation Flow cytometry (FISH-Flow)^{15,16,20,21} provides a powerful tool to examine the specific contribution of HIV-1 genomic RNA (vRNA) in inducing cell death. Unlike previous single cell HIV-1 flow cytometry-based studies that could detect only viral protein production and the translationally competent reservoir, FISH-Flow allows for the delineation of the contribution of the previously under characterised transcriptionally competent cells that produce vRNA, can trigger innate immune responses and may or may not express viral proteins^{19,22}. The single cell analysis thus provides an additional layer of insight when studying the contribution of vRNA to apoptosis.

DEAD-box polypeptide 3, X-Linked, herein referred to as DDX3, is a host protein belonging to the DEAD-box (Asp-Glu-Ala-Asp) family of ATP-dependent RNA helicases. It is involved in all aspects of RNA metabolism including processing, transport and translation, as well as in cell cycle

progression, stress response, innate immune sensing and apoptosis²³⁻²⁵. DDX3 has been implicated in several cancers due to its oncogenic function, but also plays a dual role in cancer progression because of its tumour suppressive activity²⁶⁻³⁰. Moreover, DDX3 plays distinct roles in HIV-1 infection by enhancing viral RNA gene expression, but also in activating components of the innate antiviral signalling pathway³¹. During HIV-1 replication, DDX3 has an integral function in the nucleocytoplasmic export of the genomic unspliced viral RNA (vRNA)^{32,33} as well as in vRNA translation in the cytoplasm³⁴⁻³⁶. In dendritic cells, DDX3 senses abortive HIV-1 RNA transcripts to induce type-I interferon immune responses via mitochondrial antiviral signalling protein (MAVS)³⁷. Because of its widely described roles in viral replication as well as in tumorigenesis, DDX3 has thus emerged as an attractive target for both anti-cancer and antiviral drugs^{27,38}.

Due to DDX3's roles in both HIV-1 RNA metabolism as well as in the regulation of apoptosis, we hypothesized that treatment of HIV-1-infected cells with small molecule inhibitors of DDX3 would inhibit vRNA export and translation; while the residual vRNA would activate innate antiviral immune signalling pathways and trigger apoptosis of vRNA-expressing cells, thereby resulting in a depletion of the viral reservoir.

Here we evaluated the effects of DDX3-inhibition on the latent HIV-1 reservoir using two clinically advanced inhibitors of DDX3, RK-33 and FH-1321, which target the ATPase and RNA-binding domains of DDX3 respectively. Pharmacological inhibition of DDX3 reversed HIV-1 latency in the latent HIV-1-infected J-Lat 11.1 cell line, in ex vivo latently infected CD4+ T cells, and in CD4+ T cells obtained from cART-suppressed HIV-1-infected donors via NF-κB activation. DDX3 inhibitor-mediated HIV-1 latency reversal was observed predominantly at the RNA level, which is consistent with the role of DDX3 as an inhibitor of vRNA export and translation. Chemical inhibition of DDX3 resulted in induction of IRF3 phosphorylation,

upregulation of IFN β expression and apoptosis in vRNA-expressing cells. In accordance with its pharmacological inhibition, depletion of DDX3 via shRNA-mediated knockdown in J-Lat cells also reversed HIV-1 latency and induced IFN β expression. RNA sequencing analysis of primary CD4⁺ T cells obtained from uninfected independent donors revealed significant downregulation of the inhibitor of apoptosis protein BIRC5 and Heat Shock protein 70 (HSP70) HSPA1B upon DDX3 inhibition. Importantly, treatment of latent HIV-1-infected cells with DDX3 inhibitors resulted in selective induction of apoptosis in vRNA-expressing cells but not in the uninfected/bystander cells. We quantitated the impact of treatment with DDX3 inhibitors on the inducible latent HIV-1 reservoir in CD4⁺ T cells obtained from cART-suppressed people living with HIV-1 (PLWHIV) in an *in vitro* culture model using three different methods of reservoir quantitation. Strikingly, treatment with DDX3 inhibitors over five days resulted in an approximately 50% reduction of the inducible reservoir as determined by quantitation of cell associated (CA) HIV-1 RNA, by *tat/rev* induced limiting dilution assay, as well as at the single cell level using FISH-Flow technology. These results demonstrate that pharmacological inhibition of DDX3 induces latency reversal and selective apoptosis of latent HIV-1-infected cells and serve as proof-of-concept that ICD inducers can decrease the inducible HIV-1 reservoir in infected patient cells *ex vivo*.

RESULTS

DDX3 inhibition induces viral reactivation in J-Lat 11.1 cells

Our initial screening studies focussed on examining whether pharmacological inhibition of DDX3 can affect proviral reactivation in a cell line model of HIV-1 latency, J-Lat 11.1. This model is a Jurkat-derived cell line that contains a latent integrated copy of the HIV-1 provirus defective in *env* with a GFP reporter in place of the *nef* open reading frame³⁹. J-Lat 11.1 cells harboured a basal frequency of GFP positive cells at <7.5 % that was reactivated by treatment with the PKC agonist phorbol myristate acetate (PMA) to >80% (Supplementary Fig. 1a). J-Lat 11.1 cells were treated with increasing concentrations (0.5 – 2 µM) of the DDX3 inhibitor RK-33 that has been developed for cancer treatment. RK-33 binds to the ATPase domain of DDX3 and is reported to improve radiation sensitisation of tumours in models of lung cancer, colorectal cancer, prostate cancer and Ewing's carcinoma^{27,28,40-44}. Interestingly, treatment with RK-33 alone induced viral reactivation in a dose dependent manner, with approximately 18% of cells producing GFP when treated with 2 µM RK-33 (Fig. 1a), thus unravelling a novel role for DDX3 inhibitors as LRAs. A larger latency reversal activity of RK-33 was observed at the RNA level with a 70-fold and 25-fold increase in the relative expression of the HIV-1-promoter-controlled GFP and HIV-1 genomic vRNA (*Pol*) transcripts respectively as quantified by RT-qPCR (Fig. 1b and c). Since DDX3 has been reported to play important roles in the nucleocytoplasmic export and translation of HIV-1 vRNA^{32,34-36}, we hypothesized that RK-33 could also influence HIV-1 gene expression at a post-transcriptional level by impairing either vRNA export or translation. To investigate this, we conducted FISH-Flow after treatment of J-Lat 11.1 cells with 2 µM RK-33 for 18 hours. Using probes that amplify and allow identification and quantification of viral RNA expression in cells, FISH-Flow allows for the simultaneous detection of distinct populations: i) latent cells, which

express neither viral RNA nor viral protein (vRNA-/GFP-), ii) efficiently reactivated cells, which express both HIV-1 viral RNA and proteins (vRNA+/GFP+), iii) transcriptionally competent viral RNA expressing cells with either untranslated vRNA or a block in post-transcriptional vRNA processing and viral protein expression (vRNA+/GFP-), and iv) cells only expressing GFP from multiply spliced viral RNA transcripts (vRNA-/GFP+) (Fig. 1d). Thus, FISH-flow gives an additional layer of insight on vRNA-regulation and given DDX3's previously characterised roles in post-transcriptional regulation of vRNA metabolism, FISH-flow that uses RNA-expression as a readout is the most appropriate tool to investigate the effects of DDX3 inhibition on HIV-1. On average, under uninduced conditions, only 3% of cells constitutively produced vRNA, whereas vRNA was produced in more than 80 % of cells upon PMA stimulation (Fig. 1d and e). Treatment with 2 μ M RK-33 resulted in expression of vRNA in approximately 15% of J-Lat cells (Fig. 1d and e), corroborating its latency reversal activity. Interestingly, ~8% of cells were observed in the vRNA+/GFP- quadrant, corresponding to ~42% of all vRNA+ cells (Fig. 1d and e). In contrast, merely 0.02% of the vRNA-expressing PMA-treated cells did not express GFP (Fig. 1d and e). This data indicates a post-transcriptional block in vRNA metabolism upon DDX3 inhibition. In order to determine if this block was at the level of nucleocytoplasmic export, we seeded the cells that underwent FISH-Flow analysis on a coverslip and observed them by confocal microscopy. In representative images, we observed that the vRNA+/GFP- cells in RK-33-treated conditions contained vRNA sequestered in the nucleus, while in double positive cells in both the PMA and RK-33-treated condition, vRNA was present in the cytoplasm of cells (Supplementary Fig. 1b). GFP is expressed from the multiply spliced viral RNA transcript and the full length vRNA codes for the viral protein pr55Gag³⁹. Therefore, in order to further validate that RK-33 treatment affects post-transcriptional metabolism of the vRNA, we measured pr55Gag expression in cells treated

with RK-33 by Western blot and did not observe significant upregulation of pr55Gag expression at a protein level (Supplementary Fig. c and d) despite vRNA expression at an RNA level (Figure 1c-e). Therefore, DDX3 inhibition by RK-33 hinders nucleocytoplasmic export of the vRNA and viral protein expression, thereby highlighting the importance of using vRNA expression and not viral protein production as a marker for HIV-1 infection when investigating the effects of DDX3 inhibitors.

DDX3 has previously been reported to have cell-type dependent differential effects on the regulation of the NF- κ B pathways, and has been implicated in binding to the p65 subunit thus inhibiting NF- κ B-mediated transcription^{45,46}. In order to determine if RK-33 is capable of activating NF- κ B, Jurkat cells were nucleofected with firefly luciferase reporter plasmids either containing or lacking NF- κ B consensus sites upstream of a minimal promoter, along with an internal Renilla control plasmid. Cells were then either mock-treated or treated with 2 μ M RK-33 for 18 hours. Treatment with RK-33 resulted in a modest increase in relative luciferase expression in the NF- κ B reporter transfected cells as compared to the mock-treated cells (Supplementary Fig. 1e). The NF- κ B pathway was also activated in J-Lat 11.1 cells treated with RK-33 as is evident by an upregulation of the NF- κ B target genes MMP9, IL-8 and IL-10 by 19, 2.5 and 8-fold respectively (Fig. 1f and g and Supplementary Fig. 1f). Our data therefore suggests that the DDX3 inhibitor RK-33 acts as a latency reversing agent that reactivates the HIV-1 provirus via activation of NF- κ B.

Fig. 1

Fig. 1. DDX3 inhibition reverses HIV-1 latency in J-Lat 11.1 cells

a J-Lat 11.1 cells were treated with increasing concentrations of the DDX3 inhibitor RK-33. % of reactivation, monitored by GFP production, was quantified by Flow cytometry. Error bars represent mean $\pm$ SD of at least three independent experiments with at least 10000 cells counted per treatment (Paired, two-tailed *t*-test). The relative mRNA expression levels of **b** GFP and **c** Pol

200 in the RK-33-treated J-Lat cells were quantified by RT-qPCR. Error bars represent mean $\pm$ SD of
 201 three independent experiments (Unpaired, two-tailed *t*-test). **d** Representative FISH-Flow dot-
 202 plots from an independent experiment of J-Lat cells treated with DMSO (Mock), PMA or 2 μ M
 203 RK-33. **e** The % of vRNA expressing cells (GFP- or GFP+) as treated in (a) were quantified. Error
 204 bars represent mean $\pm$ SD of three independent experiments with at least 10000 cells counted per
 205 treatment (Unpaired, two-tailed *t*-test). Relative **f** MMP9 and **g** IL-8 mRNA expression levels from
 206 cells treated as in (a) were quantified by RT-qPCR. Error bars represent mean $\pm$ SD of three
 207 independent experiments (Unpaired, two-tailed *t*-test).

DDX3 inhibition results in increased cell death in vRNA-expressing cells

In order to further characterise the impact of DDX3 inhibition and, hence DDX3 function, in HIV-1 latency, we performed shRNA-depletion of DDX3 in J-Lat 11.1 cells and monitored latency reversal and NF- κ B activation. Lentiviral transduction of J-Lat11.1 cells with shRNA against DDX3 (shDDX3) resulted in a 90% decrease in DDX3 mRNA expression and a 80% decrease in DDX3 protein expression compared to the cells treated with scrambled shRNA (shControl) as quantified by RT-qPCR and Western blot respectively (Fig. 2a and b and Supplementary Fig. 2a). DDX3-depleted cells demonstrated a 2-fold increase in GFP expression as compared to the shControl transduced cells (Fig. 2c), thereby confirming that inhibition of DDX3 reverses HIV-1 latency. Latency reversal (Pol and GFP) and NF- κ B activation (IL-10, IL-8 and MMP9) were also measured by RT-qPCR in DDX3-depleted cells and a significant increase in GFP and vRNA (Pol) mRNA expression was observed compared to mock-treated cells, reaffirming latency reversal at a transcriptional level (Fig. 2d). Moreover, similar to our observations with the chemical inhibition of DDX3 with RK-33, NF- κ B targets genes IL-10, IL-8 and MMP9 were significantly upregulated in DDX3-depleted cells as compared to the control (Fig. 2d).

During viral infection, single stranded RNA is recognised by RIG-I that induces downstream innate antiviral responses mediated by NF- κ B and IRF-3 resulting in IFN- β expression⁴⁷⁻⁴⁹. We investigated whether these effectors are activated by HIV-1 vRNA in absence of DDX3. shRNA-mediated depletion of DDX3 resulted in a significant two-fold increase in IFN- β mRNA expression compared to the mock-treated cells (Fig. 2d). Similarly, chemical inhibition of DDX3 using 2 μ M RK-33 resulted in modest upregulation of IFN- β expression in J-Lat 11.1 cells (Supplementary Fig. 2b). Interestingly, Jurkat cells that do not express vRNA did not demonstrate

any significant upregulation of IFN- β upon RK-33 treatment, suggesting that IFN- β induction is dependent on vRNA expression (Supplementary Fig 2b).

To enrich for vRNA-expressing cells and examine the specific contribution of HIV-1 vRNA to the activation of innate immune pathway components during DDX3 inhibition, we sorted J-Lat 11.1 cells into vRNA low and vRNA high populations by FACS following treatment with 2 μ M RK-33 as shown (Fig 2e). Our gating strategy was based on GFP expression, which resulted in two populations of cells; vRNA low (in which 96% of cells were vRNA negative) and vRNA high (where 68% of cells were vRNA positive). As expected, the vRNA high J-Lat 11.1 sorted cells contain ~300-fold more vRNA (Pol) than the vRNA low population (Fig. 2f). The vRNA high population demonstrated an induction of the innate antiviral signalling pathway components RIG-I and MAVS, consistent with previous work demonstrating HIV-1 vRNA's ability to activate these pathways (Fig. 2g)^{17,18}. Interestingly, a concomitant significant phosphorylation of IRF3 was also observed in the vRNA-high expressing cells, confirming the activation of innate antiviral signalling pathways in vRNA-expressing cells (Fig. 2h and i). The phosphorylation of IRF3 in combination with NF- κ B activation results in production of type I interferons⁴⁷⁻⁴⁹. In agreement, we observed a significant increase in IFN- β mRNA expression in the vRNA-high cell population (Fig. 2j). The characterised role of IFN- β in contributing to apoptosis, also during viral infection⁵⁰⁻⁵² together with RK-33's described roles in inducing cell death⁴⁰, prompted us to examine whether the vRNA high cells are more susceptible to apoptosis. Concomitant with the observed increased viral RNA expression, we also observed an approximately 35% decrease in the ratio of the anti-apoptotic Bcl2 to the pro-apoptotic Bax mRNA expression levels in the HIV-1 vRNA-high population, indicating that the vRNA expressing cells have a higher susceptibility to undergo apoptosis (Fig. 2k). To further probe the selectivity of cell death, J-Lat 11.1 cells and parental

Jurkat cells lacking integrated HIV-1 provirus and vRNA were treated with increasing concentrations of RK-33 (0.5 – 2 μ M). Eighteen hours post treatment, cells were stained with Hoescht 33342 and the percentage of viable cells was quantified by flow cytometry. We observed a dose-dependent increase in cell death in RK-33-treated J-Lat cells compared to parental Jurkat cells, most strikingly at 2 μ M RK-33 (Fig. 2i). In this condition, cell death was observed in 70 % of J-Lat 11.1 cells, but only in 30 % of Jurkat cells, representing a significant increase in cell death in HIV-1-infected cells. Since they are a cancer-derived cell line, the viability of Jurkat cells was also affected upon treatment with the RK-33, albeit not as much as the J-Lat 11.1 cells (Supplementary Figure 2c). In comparison, RK-33 had negligible effects on the viability of primary CD4⁺ T cells (Supplementary Figure 2c). Our data therefore indicates that DDX3 inhibition results in latency reversal, activation of NF- κ B and IRF3, leading to induction of IFN- β expression and a pro-apoptotic state, thereby rendering vRNA-expressing cells more susceptible to cell death during vRNA expression.

Fig. 2

Fig. 2. DDX3 inhibition induces IRF3 phosphorylation, IFN β expression and cell death in J-Lat 11.1 cells

a J-Lat 11.1 cells were transduced with a control lentiviral vector expressing a scrambled shRNA (shControl) or with lentivirus expressing shRNA against DDX3 (shDDX3) and relative DDX3 mRNA expression was quantified by RT-qPCR. Error bars represent the mean $\pm$ SD of three independent experiments (Unpaired, two-tailed *t*-test). **b** Representative Western blots depicting DDX3 and GAPDH in shControl and shDDX3 conditions. **c** The % of reactivation monitored as GFP production from cells as treated in (a) were quantified by Flow cytometry. Error bars represent mean $\pm$ SD of three independent experiments with at least 10000 cells counted per treatment (Paired, two-tailed *t*-test). **d** In cells treated as in (a), relative GFP, Pol, IL-10, IL-8, MMP9, IRF3 and IFN β mRNA expression levels in shDDX3 treated cells were quantified by RT-qPCR and normalised to the shControl. Error bars represent mean $\pm$ SD of three independent experiments (Unpaired, two-tailed *t*-test). **e** RK-33-treated J-Lat cells were sorted into GFP- (vRNA low) and GFP+ (vRNA high) fractions and the relative mRNA expression of vRNA using primers against **f** Pol and **g** RIG-I and MAVS expression were quantified by RT-qPCR. **h** Representative Western blots depicting phosphorylated IRF3, total IRF3 and GAPDH protein expression in RK-33-treated vRNA low and vRNA high populations. **i** Quantification of the densitometric analysis of P-IRF3 to GAPDH protein expression ratios from 2h. Error bars represent mean $\pm$ SD from three independent experiments (Unpaired, two-tailed *t*-test). The relative expression of **j** IFN β mRNA and **k** ratios of Bcl2 and Bax mRNA expression in RK-33-treated vRNA low and vRNA high populations were quantified by RT-qPCR. **l** % Cell death was measured in Jurkat vs. J-Lat cells treated with increasing concentrations of RK-33 by flow cytometry. Error bars represent the mean

290 $\pm$ SD of at least three independent experiments with at least 10000 cells counted per treatment

291 (Paired, two-tailed *t*-test).

292

DDX3 inhibition downregulates genes involved in cell survival

The inhibition of DDX3 helicase function, i.e., dsRNA unwinding, can be achieved by competitive inhibition of the ATP or RNA binding sites. RK-33 was demonstrated to inhibit RNA helicase activity in a concentration-dependent manner reducing ATP consumption in enzymatic assays⁴⁰. A new class of inhibitors competitive for the DDX3 RNA binding site have been reported by Radi et. al.⁵³ and were further developed leading to identification of the potent and selective compound FH-1321 (compound 16d in³⁸), that specifically targets the DDX3 RNA binding site with no effect in its ATPase activity³⁸. A hypothetical binding model obtained by molecular docking calculation for both RK-33 and FH-1321 depicts the predicted binding of RK-33 to the ATP binding site of DDX3 while, FH-1321 binds the RNA binding site (Fig. 3a, Supplementary Fig. 3a and b). For both molecules, the downstream effect is inhibition of the RNA helicase activity of DDX3^{40,53}. We therefore investigated the potential function and mechanism of action of RK-33 and FH-1321 in HIV-1 reactivation and reservoir dynamics in the more relevant primary CD4+ T cells. First, we observed no significant decrease in viability when primary CD4+ T cells from three healthy donors were treated with up to 10 μ M of either compound (Supplementary Fig. 3c). We also cultured CD4+ T cells in the presence or absence of 2 μ M RK-33 or 1 μ M FH-1321, for 5 days and observed no significant differences in cell viability between the DDX3 inhibitor-treated and mock-treated conditions (Supplementary Fig. 3d). To gain insight into the molecular mechanism by which DDX3 inhibition may induce cell death in HIV-1-infected cells, we treated primary CD4+ T cells obtained from two healthy donors with RK-33 and FH-1321 and performed RNA-sequencing. Minimal changes in gene expression were observed 4 hours post treatment with 2 μ M RK-33 or 1 μ M FH-1321 with one and five differentially expressed genes respectively with a 1.5-fold difference in expression, and a false discovery cut-off rate set to 0.05 (Supplementary Fig.

3e - f). At 18 hours post treatment: primary CD4⁺ T cells treated with 1 μ M FH-1321 displayed only 34 genes differentially expressed while treatment with RK-33 (2 μ M) resulted in 39 genes differentially expressed in both donors (Fig. 3b - d and Tables 1 and 2). Interestingly, the majority of the differentially expressed genes were common to both the RK-33 and FH-1321 treatments (n=23). Since these effects are common between compounds belonging to two different classes of DDX3 inhibitors they are bound to be specific to inhibition of DDX3 helicase activity (Fig. 3e). Notably, the overall change in gene expression was very limited, consistent with the minimal potential for off target or cytotoxic effects associated with use of these compounds. Interestingly, two of the differentially expressed genes significantly downregulated in CD4⁺ T cells in response to RK-33, the inhibitor of apoptosis protein BIRC5 and HSPA1B (heat shock protein 70 (Hsp70)), have been previously implicated to play a role in HIV-1 induced cell death. BIRC5, which is also significantly downregulated in response to FH-1321 treatment, has been previously demonstrated to be upregulated in latent HIV-1-infected cells, and its inhibition resulted in increased cell death of HIV-1-infected cells⁵⁴. Also involved in regulating apoptosis in infected cells, Hsp70 was shown to inhibit apoptosis induced by the HIV-1 protein Vpr⁵⁵. Consistent with the observed DDX3-mediated induction of NF- κ B, HSP70 was also shown to inhibit HIV-1 gene expression⁵⁶, possibly via suppression of NF- κ B signalling through its interaction with HSP70 binding protein 1⁵⁷. RK-33 and FH-1321-mediated downregulation of BIRC5 and RK-33-mediated HSPA1B downregulation was confirmed at the RNA level by RT-qPCR in six additional uninfected donor CD4⁺ T cells (Fig. 3f) and at the protein level by Western blot analysis in CD4⁺ T cells from 3 donors (Fig 3 g-i and Supplementary fig. 3g). We also conducted shRNA-mediated depletion of DDX3 in CD4⁺ T cells from three donors and observed a decrease in DDX3 protein expression upon shDDX3-containing lentiviral transduction (Fig 3h and i). This also corresponded to a

decrease in expression of BIRC5 at both protein and mRNA levels, but no decrease in HSPA1B at an mRNA level (Fig 3j and Supplementary fig. 3h-i). To ensure that DDX3 inhibitors do not induce T cell activation, we examined CD25 expression upon treatment with RK-33 and FH-1321 (Supplementary Fig. 3j). Consistent with the minimal effects observed with the RNA sequencing, treatment with DDX3 inhibitors did not result in induction of T cell activation, nor did DDX3 inhibition compromise effector function in CD4⁺ T cells (Supplementary Fig. 3k and l) or CD8⁺ T cells (Supplementary Fig. 4a and b) as determined by flow cytometry measuring IL-2 and IFN γ upon PMA-induced activation. Moreover, treatment with DDX3 inhibitors did not affect capacity for proliferation in either CD4⁺ T or CD8⁺ T cells (Supplementary Fig. 4c-f) as determined after induction/stimulation with CD3/CD28. We also confirmed that DDX3 inhibition at the concentrations used does not affect *de novo* host cell translation in primary CD4⁺ T cells (Supplementary Fig. 4g and h). Finally, we determined if treatment of CD4⁺ T cells with DDX3 inhibitors could induce NF- κ B activation by quantifying levels of target genes by RT-qPCR. Treatment with RK-33 and FH-1321 resulted in induction of the targets IL-8 and MMP9 mRNA expression, and whereas FH-1321 treatment induced expression of IL-8 and IL-10 mRNA expression (Supplementary Fig. 4i-k).

Fig. 3

a. Molecular docking of RK-33 and FH-1321 to pre-unwound DDX3 confirmation as predicted by AutoDock Vina. DDX3 domain 1 is shown as pale green cartoon, domain 2 is shown as pale blue cartoon and surface color code is pink for ATP-binding residues and orange for RNA-binding residues. Color code for RK-33 is yellow for carbon, red for oxygen, dark blue for nitrogen. Color code for FH-1321 is green for carbon, red for oxygen, dark blue for nitrogen. The predicted hydrogen bond between FH-1321 and Lysine 541 from DDX3 RNA-binding pocket is indicated with a dashed line. **b** Table of differentially expressed genes upon treatment of CD4⁺ T cells with DDX3 inhibitors. Volcano plot of differentially expressed genes 18 hours post-treatment with **c** RK-33 and **d** FH-1321. **e** Venn diagram of overlapping differentially expressed genes 18 hours post treatment with DDX3 inhibitors. **f** CD4⁺ T cells from healthy donors were treated with DMSO (Mock), RK-33 and FH-1321 and the relative expression of BIRC5 and HSPA1B mRNAs were quantified by RT-qPCR. Error bars represent the mean $\pm$ SD of independent experiments with cells from 6 different donors (Unpaired, two-tailed *t*-test). **g** Representative Western blots of CD4⁺ T cells treated with 2 μ M RK-33 or 1 μ M FH-1321 depicting BIRC5 and **h** HSP70 expression with loading controls as indicated. **i** Quantification of the densitometric analysis of BIRC5 protein expression from cells as treated in Fig 2g. Error bars represent the mean $\pm$ SD from three donors. (Unpaired, two-tailed *t*-test) **j** Representative Western blots depicting DDX3, BIRC5 and GAPDH protein levels from CD4⁺ T cells stimulated with CD3-CD28-coated beads and infected with a control lentiviral vector (shControl) or a lentiviral vector expressing shRNA against DDX3 (shDDX3).

DDX3 inhibitors reactivate and selectively kill HIV-1-infected cells in a primary model of latency

Given our observations that DDX3 inhibition reverses latency, induces more cell death in the J-Lat model, and doesn't affect primary CD4⁺ T cell function, we wondered if we could use the DDX3 inhibitors to reactivate the provirus and induce cell death in a primary CD4⁺ T cell model of HIV-1 latency, developed by Lassen and Greene⁵⁸⁻⁶⁰ (Fig. 4a). In this model of HIV-1 latency, the virus used to infect the primary CD4⁺ T cells contained a luciferase reporter inserted in the *nef* open reading frame, which is encoded by the multiply-spliced vRNA transcript (similar to the GFP in the J-Lat cells). We treated latently-infected cells with 2 μ M RK-33, 1 μ M FH-1321 or PMA-ionomycin (as a positive control) and monitored latency reversal 18 hours post treatment by FISH-Flow²², RT-qPCR using primers against the Pol region of the vRNA and relative luciferase expression (Fig. 4a). To quantify ICD, we also co-stained cells with a fixable viability dye and either with a fluorophore-conjugated antibody that detects AnnexinV or cleaved Caspase3/7, both markers for host cell apoptosis (Gating strategy in Supplementary Fig. 5a). FISH-Flow has a high specificity for the target HIV-1 vRNA with negligible background in the uninfected CD4⁺T cells and a sensitivity to detect up to 10 HIV-1 vRNA⁺ cells per million cells^{16,22} (Fig. 4b). In latent HIV-1-infected CD4⁺ T cells, basal levels of vRNA were produced in the uninduced (Mock) condition (~165 vRNA⁺ cells/million), with a frequency of >650 vRNA⁺ cells/million upon PMA-ionomycin stimulation, corresponding to a 4.8 (s.d. $\pm$ 3.3) fold increase (Fig. 4b and c, Supplementary Fig 5b). Treatment with the DDX3 inhibitors RK-33 and FH-1321 resulted in ~410 vRNA⁺ cells/million and ~365 vRNA⁺ cells /million respectively, corresponding to a 2.8 (s.d. $\pm$ 1.1) fold and a 2.5 (s.d. $\pm$ 1.4) fold increase in the frequency of vRNA-expressing cells as compared to the mock-treated condition (Fig. 4b and c, Supplementary Fig 5b). We also measured

intracellular vRNA (Pol) expression and multiply spliced viral RNA (msRNA) from cell lysates by RT-qPCR and observed a 12.4-fold increase in vRNA expression with RK-33, a 15.7-fold increase with FH-1321 and a 66.8 fold increase with PMA-ionomycin as compared to the mock-treated cells (Fig. 4d and Supplementary Figure 5c). When treated with DDX3-inhibitors, a 1.5-fold increase in relative luciferase units as compared to the mock-treated condition was observed in both RK-33 and FH-1321-treated conditions (Fig. 4e). DDX3 influences viral gene expression at a post-transcriptional level (Fig. 1e). In agreement, the observed fold increase in luciferase expression upon DDX3 inhibition was not as high as that of vRNA expression. Together, these data demonstrate that the DDX3 inhibitors also induce latency reversal in a primary CD4⁺T cell model of HIV-1 latency. Based on our observations of increased cell death in J-Lat 11.1. cells in comparison to the Jurkat cells minimal cell death at the working concentrations in uninfected primary CD4 T-cells (Fig. 2i, Supplementary Fig. 3c and d), we sought to determine if increased cell apoptosis could be observed specifically in the vRNA-expressing primary CD4⁺ T cells in the *in vitro* model of HIV-1 latency. For this we quantified the percentage of AnnexinV positive cells in cultures treated with mock, RK-33, FH-1321 or PMA-Ionomycin. Because FISH-Flow is a single cell technique, we could distinctly quantify the differential expression of the vRNA⁺ cells or the vRNA⁻/bystander cells from our latency model. In order to validate the selectivity of cell death upon drug treatment, we also quantified the percentage of AnnexinV expression in uninfected CD4⁺ T cells. Basal levels of AnnexinV and Caspase3 positivity (<1%) were observed in the uninfected cells or the vRNA⁻ bystander cells (Fig. 4f and g). Of the vRNA⁺ cells, 4.8 (s.d. $\pm$ 4) % were AnnexinV positive in the cultures treated with PMA-ionomycin, indicating that viral reactivation might already make the cells more susceptible to cell death (Fig. 4f). Interestingly, in the cultures treated with RK-33 and FH-1321, 11.1 (s.d. $\pm$ 8.1) % and 9.6 (s.d. $\pm$ 4.5) % of vRNA⁻

expressing cells respectively, were AnnexinV positive (Fig. 4f). In order to further validate that the vRNA+ cells are indeed undergoing apoptosis, we repeated these studies in three additional donors and measured the expression of cleaved Caspase3/7 by FISH-Flow. We observed that 40.5 (s.d. $\pm$ 8.5) % and 38.9 (s.d. $\pm$ 15.5) % of RK-33 and FH-1321 treated cells were cleaved Caspase3/7 positive as compared to the 13.3 (s.d. $\pm$ 5.9) % positive cells in the Mock-treated condition (Fig. 4g). To determine if BIRC5 downregulation plays a role in latency reversal, we treated J-Lat 11.1 cells with the BIRC5 inhibitor YM155⁶¹ but did not observe significant latency reversal, suggesting that BIRC5 plays a more prominent role in the death of vRNA-expressing cells rather than their latency reversal (Supplementary Figure 5d). We were unable to observe vRNA+ mediated effects on the relative expression of the anti-apoptotic protein Bcl2 and the pro-apoptotic protein Bax by RT-qPCR (Supplementary Fig. 5e) since only a small fraction of cells (<1%) is HIV-1-infected within the total population, further highlighting the importance of FISH-Flow which enables investigation of HIV-1 induced selective cell death at the single cell level. Together, this data shows that DDX3 inhibitors exacerbate apoptosis triggered by the vRNA and selectively induce cell death in vRNA-expressing cells, while uninfected cells are not affected.

Fig. 4

Fig. 4. DDX3 inhibition has LRA and ICD activity in a primary model of HIV-1 latency

a Schematic for latency establishment in primary human CD4 + T cells using the Lassen and Greene model. Latent HIV-1-infected cells were treated on Day 5 with DMSO (Unstimulated), PMA/Ionomycin, and the DDX3 inhibitors 2 μ M RK-33 and 1 μ M FH-1321. Uninfected cells were used as a negative control. **b** Representative FISH-Flow dot plots of cells as treated in (a) representing 50000 cells from each condition. **c** The frequency of vRNA expressing cells per million as depicted in (b) were quantified. Individual donors are represented by the same colour. Error bars represent the mean $\pm$ SD of independent experiments using cells from at least 6 different donors, with a minimum of 100000 events acquired for each condition (Paired, two-tailed, Wilcoxon test). **d** The relative Pol mRNA (vRNA) expression levels from cells as treated in (a) were quantified by RT-qPCR. Error bars represent the mean $\pm$ SD of independent experiments with cells from 5 different donors in duplicate (Unpaired, two-tailed *t*-test). **e** Relative luciferase activity of cells as treated in (a) was measured and normalised to the mock treated condition. Error bars represent the mean $\pm$ SD of independent experiments with cells from 5 different donors in duplicate (Unpaired, two-tailed *t*-test). **f** The percentages of AnnexinV positive cells from the uninfected, infected vRNA- fractions, or infected vRNA+ cells as quantified by FISH-Flow. Error bars represent the mean $\pm$ SD of independent experiments with cells from 6 different donors, with a minimum of 100000 events acquired for each condition (Paired, two-tailed *t*-test). **g** The percentages of cleaved Caspase3 positive cells from the infected vRNA- fractions or infected vRNA+ cells as quantified by FISH-Flow. Error bars represent the mean $\pm$ SD of independent experiments with cells from at least 3 different donors, with a minimum of 100000 events acquired for each condition (Paired, two-tailed *t*-test).

DDX3 inhibitors induce latency reversal in CD4+ T cells from HIV-1-infected donors

To further investigate the clinical potential of DDX3 inhibitors we examined their ability to induce latency reversal and selective cell death in CD4+ T cells from chronic HIV-1-infected donors on suppressive cART with undetectable viral loads for at least 12 months (minimum n=6). Following isolation from cryopreserved PBMCs obtained by leukapheresis of HIV-1-infected donors, CD4+ T cells were treated according to the schematic in Fig. 5a. Briefly, cells were cultured either with mock treatment, 2 μ M RK-33 or 1 μ M FH-1321 overnight in the presence of an HIV-1 integrase inhibitor (Raltegravir). Cells were collected 18 hours post treatment and analysed by FISH-Flow using probes against the vRNA, a viability stain, and antibodies directed against AnnexinV to quantify viral reactivation and selective early apoptosis using a similar gating strategy as described in Supplementary Fig. 5a. A nested RT-qPCR was also performed to measure cell-associated vRNA with primers targeting the Gag region of the vRNA. Compared to a frequency of 9.5 (s.d. $\pm$ 4.8) vRNA-expressing cells per million (mock-treated conditions), 28.9 (s.d. $\pm$ 9), 22 (s.d. $\pm$ 4.5) and 52.8 (s.d. $\pm$ 22.6) vRNA+ cells per million were observed in the RK-33, FH-1321 and PMA-Ionomycin treated cells respectively; corresponding to a 3.6 (s.d. $\pm$ 12.1) fold and a 2.7 (s.d. $\pm$ 1) fold increase in the percentage of vRNA-producing cells in RK-33 and FH-1321-treated conditions respectively (Fig. 5b and c, Supplementary Fig 6a). Importantly, 28.6 (s.d. $\pm$ 13.5) % and 34.8 (s.d. $\pm$ 10.3) % of vRNA+ cells in the RK-33 and FH-1321 conditions were AnnexinV positive, while all the vRNA- populations had <1% AnnexinV positivity (Fig. 5d). When LRA activity was measured by RT-qPCR, significantly higher copies vRNA per μ g RNA were observed upon RK-33 and FH-1321 treatment (Fig. 5e, Supplementary Fig. 6b). We also validated that both BIRC5 and HSPA1B mRNA expression was significantly downregulated upon RK-33 treatment while FH-1321 treatment resulted in decreased expression of BIRC5 (Supplementary Fig. 6c and d).

489 Therefore, treatment with DDX3 inhibitors also demonstrated latency reversal activity and
490 selective cell death in vRNA-containing CD4+ T cells from HIV-1-infected donors.

491

Fig. 5

Fig. 5. DDX3 inhibition reverses latency in CD4+ T cells from HIV-1-infected donors and selectively induces cell death

a Schematic of experiment to test LRA and ICD activity of DDX3 inhibitors in samples from PLWHIV. CD4+ T cells isolated from HIV-1-infected donors were treated with DMSO (Unstimulated), PMA/Ionomycin, and the DDX3 inhibitors RK-33 and FH-1321. For all graphs, different donors are represented by their individual colours consistently as described in Table 3 **b** Representative FISH-Flow dot plots from an HIV-1-infected donor as treated in (a) representing 100000 cells from each condition. **c** The frequency of vRNA-expressing cells per million as depicted in (b) were quantified. Error bars represent the mean $\pm$ SD of independent experiments with cells from 6 different donors, with a minimum of 100000 events acquired for each condition (Wilcoxon test). **d** The percentages of AnnexinV positive cells from the vRNA- or the vRNA+ cells as quantified by FISH-Flow. Error bars represent mean $\pm$ SD from independent experiments from 6 different donors, with a minimum of 100000 events acquired for each condition (Wilcoxon test). **e** Copies of Gag mRNA / μ g RNA from cells as treated in (a) were quantified by nested RT-qPCR. Error bars represent the mean $\pm$ SD of independent experiments with cells from 7 different donors (Wilcoxon test).

DDX3 inhibition results in a reduction in the size of the inducible viral reservoir

The induction of the pro-apoptotic AnnexinV marker in HIV-1-expressing cells that we observed upon DDX3 inhibitor treatment was consistent with the notion that DDX3 treatment could result in depletion of the inducible HIV reservoir. We therefore determined whether the DDX3 inhibitor-treated, reactivated and pro-apoptotic cells were actually eliminated over time, resulting in a decrease in the size of the inducible viral reservoir *in vitro*. CD4⁺ T cells isolated from PLWHIV were cultured in the presence of the DDX3 inhibitors for five days and then treated with PMA-Ionomycin to reactivate them to maximal capacity (Fig. 6a). The size of the inducible viral reservoir upon PMA-stimulation after culturing with DDX3 inhibitors was measured by three parallel methods of reservoir quantitation: cell-associated vRNA quantification by nested Gag RT-qPCR, FISH-flow and TILDA (Fig. 6a). We first confirmed that culturing patient CD4⁺ T cells with DDX3 inhibitors for five days did not significantly impair viability (Supplementary Fig. 6e), consistent with the mild change in overall gene expression observed by RNA sequencing. Strikingly, as determined by FISH-Flow, CD4⁺ T cells cultured in presence of the DDX3 inhibitors RK-33 and FH-1321 showed a 35 (s.d. $\pm$ 24.9) % and 47.8 (s.d. $\pm$ 20.35) % decrease in the frequency of vRNA expressing cells respectively as compared to the mock-treated cells (Fig. 6b and c, Supplementary Fig 6f). Similarly, upon treatment with PMA-Ionomycin, a significant decrease in cell-associated Gag vRNA production was observed by nested RT-qPCR in the RK-33 and FH-1321-treated cells as compared to the Mock-treated cells (Fig. 6d, Supplementary Fig 6g). For three representative donors, we also conducted TILDA to quantify the inducible viral reservoir and observed a decrease in the size of the viral reservoir after five days of treatment with RK-33 (Fig. 6e-g, Supplementary figure 6h). To confirm that RK-33 and FH-1321 do not impair PMA-induced HIV-1 reactivation, we examined the effect of co-treatment with PMA and DDX3

533 inhibitors in the Lassen and Greene *in vitro* CD4⁺ T cell model of HIV-1 latency. Co-treatment of
 534 cells with PMA together with RK-33 or FH-1321 did not impair PMA-induced reactivation,
 535 confirming that the decrease in reactivation observed is indeed due to a reduced number of latently-
 536 infected cells (Supplementary Fig. 6i). Altogether, our data demonstrates that not only do DDX3
 537 inhibitors function as latency reversing agents in primary CD4⁺ T cells from HIV-1-infected
 538 donors, they also selectively induce cell death in the vRNA-expressing cells, resulting in their
 539 elimination and a decrease in the size of the inducible viral reservoir (Fig. 7).

540

Fig. 6

Fig. 6. Prolonged DDX3 inhibition can reduce the size of the inducible viral reservoir

a Schematic of experiment to test the size of the inducible viral reservoir after culturing CD4⁺ T cells from PLWHIV with DDX3 inhibitors. CD4⁺ T cells isolated from HIV-1-infected donors were cultured in the presence of the DDX3 inhibitors RK-33 and FH-1321 or mock-treated for 5 days. On Day 5, basal CA-RNA levels were first measured and then cells were maximally stimulated with PMA-Ionomycin for 12-18 hours. On Day 6, the inducible viral reservoir was measured by FISH-Flow, CA-RNA and TILDA. For all graphs, different donors are represented by their individual colours consistently as described in Table 3. **b** Representative FISH-Flow dot plots on Day 6 of cultured cells from an HIV-1-infected donor as treated in (a) representing 50000 cells from each condition. **c** The frequency of vRNA⁺ cells/million on Day 6 as depicted in (b) were quantified and normalised to the unstimulated condition. Error bars represent the mean $\pm$ SD of independent experiments with cells from 6 different donors in duplicate, with a minimum of 100000 events acquired for each condition (Wilcoxon test). **d** Copies of Gag/ μ g total RNA quantified by RT-qPCR on Day 6 as treated in (a) and depicted in (d). Error bars represent the mean $\pm$ SD of independent experiments with cells from 7 different donors (Wilcoxon test). **e** Representative TILDA results from cells treated with DDX3 inhibitors. **f** Frequency of msRNA-expressing cells as measured by TILDA and **g** fold change of the frequency of msRNA-expressing cells upon treatment with RK-33, normalised to the Mock-treated cells. Error bars represent the mean $\pm$ SD of independent experiments with cells from 3 donors.

Fig. 7

563

564 **Fig. 7. Model for latency reversal and cell death induced by DDX3 inhibition**

565 DDX3 inhibition results in NF- κ B activation and BIRC5 and HSPA1B downregulation in both
 566 uninfected bystander and latent proviral-containing cells. The HIV-1 provirus is reactivated
 567 generating vRNA that can activate innate antiviral signaling pathways, phosphorylate IRF3 and
 568 induce IFN β expression, which when combined with BIRC5 or HSPA1B downregulation, results
 569 in upregulated Bax, downregulated Bcl2, increased cleaved caspase 3 and apoptosis of the vRNA-
 570 expressing cells, but leaving the uninfected cells unharmed, thereby resulting in a reduction in the
 571 viral reservoir.

DISCUSSION

We demonstrate that the treatment of latent HIV-1-infected cells with pharmacological inhibitors of the host RNA binding protein DDX3, modestly reverses viral latency and impairs vRNA translation. This leads to accumulation of vRNA in infected cells, which activates the innate antiviral signalling pathways^{17,18}, phosphorylates IRF3 and induces the production of IFN- β that renders vRNA+ cells pro-apoptotic (Fig. 2e-k)⁵⁰⁻⁵². In combination with the DDX3 inhibition-induced downregulation of the anti-apoptotic proteins BIRC5 and HSPA1B, this results in the selective induction of apoptosis in HIV-1 vRNA-expressing cells, with minimal toxicity to uninfected/bystander cells that do not express pro-apoptotic IFN- β (Fig. 7). Importantly, we demonstrate a reduction in the size of the inducible viral reservoir when latently infected cells were cultured in presence of DDX3 inhibitors. Our data supports the proof of concept, that pharmacological induction of selective cell death in HIV-1 infected cells subsequent to latency reversal, may be a viable HIV-1 curative strategy.

The ability of pro-apoptotic molecules to induce NF- κ B pathways and reactivate HIV-1 latency is not without precedence. Second mitochondria-derived activator of caspase (SMAC) mimetics such as LCL-161, SBI-0637142, birinipant, Debio1143 and AZD5582 that target the host anti-apoptotic factors XIAP and cIAP1/BIRC2 have been demonstrated to be potent LRAs via the activation of the non-canonical NF- κ B pathways⁶²⁻⁶⁴. Some LRAs have also been demonstrated to promote cell death, as seen with benzolactam derivatives that are PKC agonists and induce apoptosis in latent HIV-1-infected cells^{65,66}. A recent report also demonstrated that romidepsin treatment in a clinical trial resulted in an increase in the frequency of apoptotic T cells⁶⁷. Therefore, the link between apoptosis and latency reversal is highly promising to further exploit as a strategy to reactivate the

viral reservoir and induce its selective elimination. The DDX3 inhibitors described in this report are such compounds that have both LRA and ICD capability and were able to decrease the size of the inducible viral reservoir.

DDX3 inhibitors are especially interesting as a potential therapeutic class of compounds for use in curative strategies against HIV-1 because they target multiple steps of the HIV-1 life cycle. In this report, we describe the effects of DDX3 inhibition on viral reactivation via NF- κ B activation, as also previously characterised⁴⁶ and in agreement with a previous study, we found DDX3 inhibitor-mediated hindering of vRNA export^{32,35}. Additionally, DDX3 inhibitors may also impair the translation of the vRNA^{34,36}. Recent studies have demonstrated that the treatment of PBMCs with DDX3 inhibitors targeting the RNA-binding site results in a decrease in released infectious viral particles and that these compounds are also effective against HIV-1 strains harbouring resistant mutations to currently approved antiretroviral drugs^{38,68}. This characteristic impairment of host cell translation is an advantage when applying DDX3 inhibitors towards an HIV-1 cure strategy since the generation of infectious viral particles is impaired and therefore treatment with DDX3 inhibitors would prevent both the unnecessary activation of the cell mediated and humoral immune responses or inflammation induced by viral production. Additionally, we demonstrate a newly characterised role for DDX3 inhibitors as ICD inducers to eliminate the viral reservoir. DDX3 inhibitors demonstrated the ability to target the HIV-1-infected cells selectively, an important characteristic when developing ICD inducers. In this work, we demonstrate that the DDX3 inhibitors have negligible effects on the viability of uninfected cells as well as on non HIV-1 vRNA containing cells from PLWHIV at the concentrations effective in reversing latency and selectively inducing apoptosis in cells harbouring HIV-1. We hypothesise that this selectivity may arise from the contribution of several factors. Firstly, DDX3 inhibition results in the activation on NF- κ B

expression and latency reversal (Fig 1). The vRNA generated upon latency reversal activates innate antiviral signalling pathways resulting in the phosphorylation of IRF3 and the production of IFN- β , thereby rendering vRNA-expressing cells pro-apoptotic (Fig 2e-k). Therefore, vRNA-producing cells are more susceptible to dying than uninfected cells that do not express IFN- β (Fig 2i). DDX3 inhibition could also abrogate its function as a pathogen recognition receptor and instead could lead to increased vRNA levels for sensing by other factors, including the RIG-I like receptors, thereby enhancing innate antiviral signalling. The second factor that contributes to the selectivity of cell death is that DDX3 inhibition downregulates the expression of the anti-apoptotic protein BIRC5 in both healthy and HIV-1-infected cells. Since, the infected cells are already pro-apoptotic due to IFN- β production, they are selectively eliminated leaving the uninfected/bystander cells unharmed. Consistent with our observations, BIRC5 has been shown to be involved in the survival of latent HIV-1-infected cells and treatment with BIRC5 inhibitors resulted in cell death of HIV-1 protein expressing cells⁵⁴. Our data is thus consistent with a model whereby BIRC5 is essential to protect cells from the additional stress induced by the presence of HIV-1. HSPA1B that codes for Heat Shock protein 70 (Hsp70) is another gene that we found significantly downregulated in CD4⁺ T cells in response to treatment with the DDX3 inhibitor RK-33. Hsp70 has been shown to protect cells from apoptosis induced by the HIV-1 protein Vpr⁵⁵. Therefore, we can speculate that an additional mechanism of RK-33 by which it promotes HIV-1 selective cell death is through downregulation of Hsp70, whose absence leads to induction of cell death in the Vpr-expressing infected cells and not in the uninfected bystander cells. Additionally, the depletion of Hsp70 via binding to HSPBP1, has been implicated in reactivation of HIV-1 via NF- κ B activation⁵⁷, providing another possible mechanism for the observed latency reversal property of RK-33. Moreover, DDX3 inhibition interferes with vRNA metabolism and

the residual vRNA that does not efficiently generate infectious viral particles could still induce cellular stress¹⁸, activate innate antiviral signalling pathways and induce IFN- β production¹⁷ and, in combination with the downregulation of factors important for survival of latently infected cells, result in the selective killing of HIV-1-infected cells. This selective toxicity is also important when promoting the translation of these compounds into clinical settings. We validated that both RK-33 and FH-1321 have negligible effect on cell viability and gene expression in primary cells and that they do not impair the effector function and proliferation of CD4+ T cells. Importantly, these compounds also do not affect CD8+ T cell effector function and proliferation so that the essential cell-mediated immune responses would not be affected during treatment. Extensive toxicology, biodistribution and pharmacokinetics of RK-33⁴⁰ and FH-1321³⁸ have been conducted in mice and rats respectively, and both demonstrate a good toxicology profile in these pre-clinical studies, thereby advocating for their translation into clinical studies. DDX3 inhibition has however been shown to induce alter the cell cycle by causing G1 cell cycle arrest, a factor not evaluated in the context of this work, but to be noted for future work or clinical translation. Next-generation DDX3 inhibitors with significantly lower IC50s have also recently been developed with a very high potential for clinical advancement⁶⁸.

We also present in this work a novel primary CD4+ T cell model that we have established as a pipeline to further investigate compounds that induce cell death and to test their abilities to reduce the size of the inducible viral reservoir using three parallel methods of reservoir quantitation (Fig. 5a). Since the ICD strategy does not depend on other components of the host immune system such as CD8+ T cells or NK cells, this system can be used to measure pro-apoptotic compounds that have previously been studied to selectively eliminate HIV-1-expressing cells. Some examples of compounds that can be tested include Bcl2 agonists such as venetoclax^{69,70}; SMAC mimetics like

birinipant, GDC-0152, and embelin ⁷¹; Benzolactam derivatives such as BL-V8-310 ⁶⁵; p38/JNK pathways activator anisomycin ¹⁸, specific autophagy-inducing peptides Tat-Bec1 and Tat-vFLIP- $\alpha 2$ ⁷²; PI3K/Akt inhibitors ⁷³; or synthesized compounds such as L-HIPPO that inhibit viral trafficking and budding of Gag ⁷⁴ that have all been implicated in killing of HIV-1 infected cells. Pharmacological inhibition of BIRC5, also one of the genes downregulated by DDX3 expression, has been demonstrated to target HIV-1-infected cells and reduce the frequency of proviral containing cells *in vitro* ⁵⁴. However, some of these treatments have been associated with global T cell activation and toxicity, selective myeloid cell type dependent activity or non-reproducibility. Moreover, these studies have not specifically investigated the contribution of the HIV-1 vRNA in inducing cell death, made possible here using FISH-Flow technology. Further investigation of these compounds, possibly in combination with DDX3 inhibitors, will be important to assess their ability to decrease the size of the inducible viral reservoir in CD4+ T cells obtained from PLWHIV using an *in vitro* model such as the one we describe in Fig. 5a, and also to investigate the contribution of the vRNA to cell death. These studies suggest that pharmacological induction of selective cell death in HIV-1-infected cells, alone or in combination with other approaches, including those that promote extracellular killing of HIV-1-infected cells may prove effective towards an HIV-1 cure.

One of the caveats of this study is that DDX3 inhibitors are modest latency reversing agents that do not maximally reactivate the HIV-1 provirus as compared to the PMA-treated cells, thereby resulting in reactivation of only a fraction of the latently infected cells and hence a partial decrease of the viral reservoir but not its elimination. Therefore, a combinatorial strategy will be important to test in future work, combining different classes of LRAs to maximally reactivate the latent HIV-1-infected reservoir together with DDX3 inhibitors with the ultimate aim to induce cell death in

all cells harbouring inducible replication competent HIV-1. Attractive candidate LRAs for inclusion in this combinatorial approach are de-repressors of HIV-1 LTR chromatin (BAF and HDAC inhibitors)⁶⁰, activators of transcription (PKC agonists), as well as facilitators of HIV-1 transcription elongation such as the newly characterised Gliotoxin⁷⁵. Using a pipeline to measure vRNA production and cell death at a single cell level, may enable identification of an optimal combination of LRA-ICDs that lead to maximal reduction of the viral reservoir.

So far more than 160 compounds have been identified with latency reversing activity, and our work has identified DDX3 inhibitors as another category of compounds to reverse viral latency⁷⁶. In addition to latency reversal, DDX3 inhibitors target multiple steps of the HIV-1 replication cycle: transcription, nucleocytoplasmic export of the vRNA, translation and generation of infectious viral particles. Importantly, they also promoted ICD and were selectively able to induce IFN- β production and apoptosis in vRNA expressing cells resulting in the decrease in size of the inducible viral reservoir. Previous combinatorial studies and clinical trials with LRAs and immune-enhancing clearance strategies demonstrated minimal effects on the clearance of the viral reservoir⁴⁻⁶. Although multiple compounds have been identified to induce apoptosis of HIV-1-infected cells¹³, no ICD inducer has been evaluated for capability to reduce the viral reservoir in PLWHIV yet. Our data support DDX3 inhibitors as a promising new class of ICD inducers that can be utilized in HIV-1 curative therapies.

MATERIALS AND METHODS

Cell culture and Reagents

Jurkat cells and J-Lat 11.1 cells (Jurkat cells containing integrated full-length HIV-1 genome mutated in *env* gene and GFP replacing *nef*)³⁹ were maintained in RPMI-1640 medium (Sigma Aldrich) supplemented with 7% FBS and 100 µg/ml penicillin-streptomycin at 37 °C in a humidified, 5% CO₂ atmosphere. J-Lat latent proviruses were reactivated by adding 10 µM of phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) to the culture media for 18 hours. Primary CD4⁺ T cells were isolated from buffy coats from healthy donors by Ficoll gradient followed by separation via negative selection with RosetteSep Human CD4⁺ T cell Enrichment kit (StemCells Technologies) according to manufacturer's instructions. After isolation, CD4⁺ T cells were maintained in RPMI-1640 medium (Sigma Aldrich) supplemented with 10% FBS and 100 µg/ml penicillin-streptomycin at 37 °C in a humidified, 5% CO₂ atmosphere. Cells were activated with 100 ng/ml PMA and 1 µg/ml Ionomycin (Sigma Aldrich). HEK293T cells were cultured in DMEM medium (Sigma Aldrich) supplemented with 10% FBS and 100 µg/ml penicillin-streptomycin at 37°C in a humidified, 5% CO₂ atmosphere. RK-33 (SelleckChem) was used at a concentration of 2 µM, unless indicated otherwise. FH-1321 was provided by First Health Pharmaceuticals and used at concentrations of 1 µM. YM155 (SelleckChem) was used at concentrations of 200 nM).

Total RNA Isolation and Quantitative RT-PCR (RT-qPCR)

Total RNA was isolated from the cells using TRIzol reagent (Thermo Fisher Scientific) according to manufacturer's instructions. cDNA synthesis was performed using Superscript II Reverse Transcriptase (Life Technologies) kit following the manufacturer's protocol. RT-qPCR was

performed using GoTaq qPCR Master Mix (Promega) following the manufacturer's protocol. Amplification was performed on the CFX Connect Real-Time PCR Detection System thermocycler (BioRad) using the following thermal cycling program starting with 3 min at 95 °C, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s. Specificity of the RT-qPCR products was assessed by melting curve analysis. Primers used for real-time PCR are listed in Table 4. Expression data was calculated using $2^{-\Delta\Delta C_t}$ method⁷⁷. GAPDH housekeeping gene expression was used for normalisation for J-Lat cell lines and Cyclophilin A was used for primary cells.

NF-κB reporter assay

To generate the plasmids used in this assay, custom gBlock gene fragments (Integrated DNA technologies) containing either the minimal mouse heat shock protein (Hspa1a) promoter, or four NF-κB target sites followed by an Hspa1a promoter were designed with flanking NheI-NcoI restriction sites and then cloned upstream of the luciferase gene in the pGL3 luciferase reporter plasmid at the NheI-NcoI sites (Promega). Jurkat cells were transfected with pBluescript II SK(+) (empty vector), pRL Renilla Luciferase Control Reporter Vector (Promega) to normalize for transfection efficiency, and either the HSP-Luc or the NF-κB-HSP-Luc plasmids by nucleofection using Amaxa Nucleofector (Amaxa AG-Lonza, Cologne, Germany) as previously described⁵⁹. Briefly, 10 million cells were centrifuged at 200 g for 10 min at room temperature, re-suspended in 100 µl of solution R, and nucleofected with 2 µg plasmid DNA (1.5 µg pBluescript II SK(+), 200 ng pRL and either Hspa1a-pGL3 or NF-κB-Hspa1a-pGL3) using program O28. Nucleofected cells were re-suspended in 5 ml of pre-warmed, serum-free antibiotic-free RPMI at 37 °C for 15 min and then plated in 6 ml of pre-warmed complete media. Twenty-four hours post-nucleofection cells were either mock-treated or treated with 2 µM RK-33. Luciferase expression was measured

24 hours post treatment in a GloMax 96 microplate luminometer (Promega) using the Dual-Glo Luciferase assay system (Promega) and normalized to *Renilla* luciferase expression. Data represent at least three independent experiments.

FISH-Flow

Cells were collected, fixed, permeabilised and subjected to the PrimeFlow RNA assay (Thermo Fisher Scientific) following the manufacturer's instructions and as described in ^{20,21}. In primary CD4⁺ T cells, cells were first stained in Fixable Viability dye 780 (Thermo Fisher Scientific) for 20 minutes at room temperature (1:1000 in dPBS) followed by either AnnexinV-450 (560506, BD Biosciences) or with 2 μ M CellEvent™ Caspase-3/7 Green Detection Reagent (Thermo Fisher Scientific) for 30 min at room temperature (1:150 in AnnexinV binding buffer-Biolegend). For both CD4⁺ T cells and J-Lat 11.1 cells, mRNA was labelled with a set of 40 probe pairs against the GagPol region of the vRNA (catalogue number GagPol HIV-1 VF10-10884, Thermo Fisher Scientific) diluted 1:5 in diluent provided in the kit and hybridized to the target mRNA for 2 hours at 40°C. Positive control probes against the house-keeping gene RPL13A (VA1-13100, Thermo Fisher Scientific) were used to determine assay efficiency. Samples were washed to remove excess probes and stored overnight in the presence of RNAsin. Signal amplification was then performed by sequential 1.5 hour, 40°C incubations with the pre-amplification and amplification mix. Amplified mRNA was labelled with fluorescently-tagged probes for 1 hour at 40°C. Samples were acquired on a BD LSR Fortessa Analyzer and gates were set using the unstimulated J-Lat 11.1 control sample or uninfected CD4⁺ T cells. Analysis was performed using the FlowJo V10 software (Treestar).

773

774 **Confocal Microscopy following FISH-Flow**

775 J-Lat 11.1 cells that underwent the FISH-Flow assay were seeded on 18 mm diameter coverslips
776 and air dried. Coverslips were mounted in ProLong Gold Antifade Reagent (Life Technologies).
777 Immunofluorescence images were acquired using a confocal microscope (Leica, SP5). All phase
778 contrast pictures were acquired using a Leica DMIL microscope and a DFC420C camera. Images
779 were analysed and processed using Fiji / ImageJ (NIH).

780

781 **Production of shRNA lentiviral vectors and transduction**

782 Lentiviral constructs containing the desired shRNA sequences (shControl - SHC002 and
783 shDDX3 -) were amplified from bacterial glycerol stocks obtained in house from the Erasmus
784 Center for Biomics and part of the MISSION® shRNA library. 5.0×10^6 HEK293T cells were
785 plated in a 10 cm dish and transfected with 12.5 µg of plasmids mix. 4.5µg of pCMVΔR8.9
786 (envelope)⁷⁸, 2 µg of pCMV-VSV-G (packaging)⁷⁸ and 6 µg of shRNA vector were mixed in 500
787 µL serum-free DMEM and combined with 500 µL DMEM containing 125 µL of 10 mM
788 polyethyleneimine (PEI, Sigma). The resulting 1 mL mixture was added to HEK293T cells after
789 15 min incubation at room temperature. The transfection medium was removed after 12 hours
790 and replaced with fresh RPMI medium. Virus-containing medium was harvested and replaced with
791 fresh medium at 36 ,48, 60 and 72 hours post-transfection. After each harvest, the collected
792 medium was filtered through a cellulose acetate membrane (0.45 µm pore) and used directly
793 for shRNA infections or stored at -80°C for subsequent use. For lentiviral transduction of J-
794 Lat 11.1 cells, 1 ml of collected virus was seeded with 2×10^6 cells in a final volume of 4 ml.

Transduced cells were selected with 1 µg/ml Puromycin 72 hours post infection and cells were collected 4 days post selection. For primary CD4⁺ T cells, cells were stimulated for 3 days with anti-CD3-CD28-coated Dynabeads (Thermo Fisher Scientific) and 5 ng/ml IL-2 (Thermo Fisher Scientific), and then resuspended with 1 ml of virus per 6 x 10⁶ cells. Transduced cells were selected with 1 µg/ml Puromycin 72 hours post infection and cells were harvested 4 days post selection.

Western blotting

At least 500000 J-Lat 11.1 cells or 2 x 10⁶ CD4⁺ T cells were lysed per condition. Cells were washed with dPBS and lysed in ice-cold lysis buffer (100 mM NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA, 0.5% Nonidet P-40, protease and phosphatase inhibitor cocktail [Roche]). Cell lysates were denatured in Laemmli sample buffer and incubated for 5 min at 95°C. The proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad). Membranes were blocked with 5% nonfat milk in Tris-buffered saline pH 7.4 and 0.5% Tween 20 (TBST) and then incubated with primary antibodies. After three washes with TBST, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Rockland Immunochemicals) and detected using Western Lightning Plus-ECL reagent (Perkin-Elmer). Signal intensity and densitometry analyses were conducted using ImageJ (NIH). The following antibodies were used: anti-Puromycin (12D10 Sigma Aldrich), anti-GAPDH (ab8245, Abcam) and anti-DDX3 (ab128206, Abcam), anti- Phospho-IRF-3 (Ser386) (37829, Cell Signalling Tech), anti-HSP70 (4872, Cell Signalling Tech), anti- IRF-3 (sc33641, Santa Cruz), anti BIRC5 (sc17779, Santa Cruz) and anti-tubulin (B7, Santa Cruz).

817

818 **Molecular docking**

819 Molecular docking analysis was used to determine the most likely binding mode of RK-33 and
 820 FH-1321 to pre-unwound DDX3 conformation. Crystal structure of human DDX3 in complex with
 821 dsRNA (PDB ID code 6O5F) in the pre-unwound confirmation was used as a template to define
 822 the receptor for the docking simulation by elimination of protein chain B and RNA domain C and
 823 D. RK-33 and FH-1321 ligand structure were built and energy minimized using the program
 824 Chimera ⁷⁹. Molecular docking of RK-33 and FH-1321 to pre-unwound DDX3 confirmation was
 825 performed using Chimera's AutoDock Vina function ⁸⁰. The resulting solutions were ranked based
 826 on highest binding affinity (or lowest binding energy). Figures were created using PyMol
 827 Molecular Graphics System, Version 1.8. 2015 (Schrödinger L).

828

829 **RNA-seq**

830 RNA was isolated using TRI Reagent (Sigma-Aldrich). RNA-seq was performed according to the
 831 manufacturer's instructions (Illumina) using the TruSeq Stranded mRNA Library Prep kit. The
 832 resulting DNA libraries were sequenced according to the Illumina TruSeq v2 protocol on an
 833 Illumina HiSeq 2500 sequencer. Reads of 50 bp in length were generated. Reads were mapped
 834 against the UCSC genome browser hg19 reference genome with HiSat2 (version 2.1.0). Gene
 835 expression was quantified using htseq-count (version 0.11.2). For all samples, at least 14.4 million
 836 reads were generated with counts on 22.6-24.2 thousand expressed genes. Differential expression
 837 analysis of the RNA-seq data was performed using edgeR package run under Galaxy
 838 (<https://bioinf-galaxian.erasmusmc.nl/galaxy/>). False discovery rate cut-off was set to 0.05 and a

fold change of ± 1.5 was counted as differentially expressed. Heat maps were generated using MORPHEUS (<https://software.broadinstitute.org/morpheus/index.html>).

Viability and Activation assays

In Jurkat and J-Lat cells, 10 ng/ml Hoechst 33342 was added to the cells and 30 min later, the viability and reactivation were quantified by measuring 405nm+ and GFP+ expression respectively by flow cytometry. In primary CD4+ T cells, to determine viability and cell activation following DDX3 inhibition, cells were collected and stained with Fixable Viability Dye eFluor® 780 (Thermo Fisher Scientific) and anti-CD25-PE (Becton Dickinson). Mock-treated and cells treated with PMA-Ionomycin were used as negative and positive controls, respectively. Cells were stained for 30 min at 4 °C, washed with PBS, and resuspended for flow cytometric analysis.

T cell proliferation and functionality assay

To analyze the effect of the LRA on CD8+ and CD4+ T cells, proliferation and cytokine expression were analyzed by flow cytometry. Primary CD8+ and CD4+ T cells were isolated from buffy coats from healthy donors by Ficoll gradient (GE Healthcare) followed by negative selection with RosetteSep Human CD8+ T Cell Enrichment Cocktail or RosetteSep Human CD4+ T Cell Enrichment Cocktail (StemCell Technologies) respectively. Isolated cells were left overnight for recovery. To analyze T cell proliferation capacity, 1 million CD8+ or CD4+ T cells were stained with 0,07 μ M CellTrace Far Red Cell Proliferation dye (Thermo Fisher Scientific) following manufacturer's instructions. Cells were then cultivated for 72 hours in either unstimulated or

stimulated conditions in the presence of the LRA, and analyzed by flow cytometry. Stimulation of T cells was performed using Anti-CD3/CD28 coated Dynabeads (Thermo Fisher Scientific) following manufacturer's protocol. Proliferation capacity was determined by a decrease in proliferation dye intensity in daughter cells upon cell division. To analyze T cell functionality by means of cytokine expression 1 million CD8⁺ or CD4⁺ T cells were left untreated or treated with the LRA for 18 hours. Cells were then left unstimulated or stimulated with 50 ng/mL PMA and 1 μ M Ionomycin for 7 hours in the presence of a protein transport inhibitor (BD GolgiPlugTM, BD Biosciences). To stain for intracellular cytokines cells were washed with PBS supplemented with 3% FBS followed by a fixation and permeabilisation step with FIX & PERM Kit (Invitrogen) following manufacturer's protocol and incubated with 1:25 BV510 anti-IL2 (563265, BD Biosciences) and PE-Cy7 anti-IFN γ (27-7319-41, eBioscience) in permeabilisation buffer for 45 minutes at 4C. Stained cells were washed with PBS supplemented with 3% FBS and analyzed by flow cytometry.

Measurement of de novo protein synthesis

De novo protein synthesis upon DDX3 inhibition was measured by the incorporation of puromycin into peptide chains⁸¹. Briefly, cells were incubated with 10 μ g/mL puromycin (Sigma Aldrich) for 10 min before cell lysis followed by Western blot according to standard procedure as previously described using antibodies against puromycin. Puromycin incorporation was assessed by summing the immunoblot intensity of all *de novo* synthesized protein bands normalised to the signal intensity of the GAPDH band. CD4⁺ T cells were treated with 10 μ g/mL Cycloheximide (Sigma Aldrich) for 4 hours to inhibit translation as a control for the technique.

882

883 **Primary CD4 + T Cell Infection and *In vitro* HIV-1 latency model generation**

884 Infections were performed using a pseudotyped virus expressing luciferase that were generated by
 885 co-transfecting HXB2 Env together with the HIV-1 backbone plasmid with a luciferase reporter
 886 (pNL4.3.Luc.R-E-) into HEK 293T cells using PEI (Polyethylenimine) transfection reagent. 48
 887 and 72 hours post-transfection, the pseudovirus-containing supernatant was collected, filtered
 888 through a 0.45 µm filter, aliquoted and concentrated by ultracentrifugation (20 000 g for 1 hour at
 889 4°C). The pellet was resuspended in RPMI-1640 and stored at -80 °C. The *in vitro* model of HIV-
 890 1 latency was set up using the Lassen and Greene method⁵⁸ as follows: CD4+ T cells were infected
 891 with the pNL4.3.Luc-R-E- virus by spinoculation (2 hours at 1200 g) 24 hours after isolation and
 892 cultured overnight in RPMI 10% FBS and 100 µg/ml penicillin-streptomycin in presence of
 893 Saquinavir Mesylate (5 µM). Eighteen hours after spin-infection cells were washed and cultured
 894 in growth media supplemented with 5 µM Saquinavir Mesylate. Three days after infection cells
 895 were treated with DDX3 inhibitors in presence of Raltegravir (3 µM). HIV-1 molecular clone
 896 pNL4.3.Luc.R-E-, HIV-1 HXB2-Env expression vector, Saquinavir Mesylate and Raltegravir
 897 were kindly provided by the NIH AIDS Reagents. HIV-1 molecular clone pNL4.3.Luc.R-E- and
 898 HIV-1 HXB2-Env expression vector were donated by Dr. Nathaniel Landau and Drs Kathleen
 899 Page and Dan Littman, respectively. Cells were harvested 24 hours after stimulation with DDX3
 900 inhibitors, washed once in PBS and either lysed for RNA extraction, used for FISH-Flow analysis
 901 or lysed in passive lysis buffer to measure luciferase activity using Luciferase Assay System
 902 (Promega). Relative light units were normalized to protein content determined by Bradford assay
 903 (Bio Rad).

904

905 **Assays with HIV-1-infected donor samples**

906 PBMCs from HIV-1-infected donors were obtained by Ficoll density gradient isolation of
 907 leukapheresed material from donors that were older than 18 years, cART-treated for at least 1 year,
 908 with viral loads below 50 copies/ml for more than 2 months. This study was conducted in
 909 accordance with the ethical principles of the Declaration of Helsinki. HIV-1-infected patient
 910 volunteers were informed and provided signed consent to participate in the study. The study
 911 protocol was approved by the Erasmus Medical Centre Medical Ethics Committee (MEC-2012–
 912 583). CD4⁺ T cell isolation was performed using negative selection with the EasySep Human
 913 CD4⁺ T cell Enrichment kit (StemCells Technologies) according to manufacturer's instructions.
 914 After isolation, CD4⁺ T cells were allowed to rest for at least 4 hours, maintained in RPMI-1640
 915 medium (Sigma Aldrich) supplemented with 10% FBS, 100 µg/ml penicillin-streptomycin and
 916 Raltegravir (3 µM) at 37 °C, in a humidified, 5% CO₂ atmosphere. Cells were treated with DDX3
 917 inhibitors or with PMA-Ionomycin as a positive control for viral reactivation (100 ng/ml PMA and
 918 1 µg/ml Ionomycin). Eighteen hours post treatment, cells were either lysed in TRIzol for RNA
 919 extraction and RT-qPCR or analysed by FISH-Flow. To measure the depletion in the size of the
 920 inducible viral reservoir, cells were cultured for 5 days in 2 µM RK-33 and 1 µM FH-1321 with a
 921 change in media and retreatment after 48 hours. Five days post treatment, media was changed, and
 922 cells were treated with PMA-Ionomycin for 12 hours and collected for TILDA, or after 18 hours
 923 for RT-qPCR and FISH-Flow.

924

925 **Cell-associated HIV RNA measurement by nested RT-qPCR**

Cell-associated HIV-1 RNA was measured as previously described with minor modifications⁸². Briefly, the first round of the PCR was performed using the primers Gag1 (5' TCAGCCCAGAAGTAATACCCATGT 3') and SK431 (5' TGCTATGTCAGTTCCCCTTGGTTCTCT 3') that amplifies a region within the HIV-1 gag gene in 25 µl of PCR mix containing 4 µl of cDNA, 2.5 µl 10X Platinum Taq buffer, 2 mM MgCl₂, 0.4 mM concentrations of deoxynucleoside triphosphates, 0.2 µl Platinum Taq and 0.3 µM each of both primers. The PCR settings were as follows: 95°C for 5 min, followed by 15 cycles of 95°C for 30 s, 55°C for 30 s, and 72°C for 1 min. The product of the first PCR was subsequently used as a template in the second, semi-nested, real-time, PCR amplification. A total of 2 µl of the first PCR product was added to a PCR mix with final volume 25 µl containing 2.5 µl 10X Platinum Taq buffer, 2 mM MgCl₂, 0.4 mM concentrations of deoxynucleoside triphosphates, 0.2 µl Platinum Taq and 0.2 µM of the primers Gag1 (5' TCAGCCCAGAAGTAATACCCATGT 3') and Gag2 (5' CACTGTGTTTAGCATGGTGT 3'), and 0.075 µM TaqMan dual-labeled fluorescent probe Gag3 (5' [6FAM]ATTATCAGAAGGAGCCACCCCAAGA[BHQ1] 3'). Real-time PCR settings were as follows: 95°C for 5 min, followed by 45 cycles of 95°C for 30s and 60°C for 1 min. The amplicon sizes were 221 bp for the first PCR and 83 bp for the second (real-time) PCR. Serial dilutions of plasmid DNA standards were used to generate a standard curve to calculate the copies of vRNA and then normalised to the amount of input RNA.

Tat/rev induced limiting dilution assay (TILDA)

TILDA was performed using a modified method as described in⁸³. Briefly, total CD4⁺ T cells were isolated from PBMCs by negative magnetic separation using EasySep Human CD4⁺ T cell

isolation kit (StemCell Technology). Following treatment for 5 days (Fig. 6a), 2×10^6 cells/ml stimulated for 12 hours with 100 ng/ml phorbol 12-myristate 13-acetate (PMA) and 1 μ g /ml ionomycin (both from Sigma Aldrich). After stimulation, CD4⁺ T cells were washed and resuspended in RPMI-1640 at serial dilutions; 1.8×10^6 cells/ml, 9×10^5 cells/ml, 3×10^5 cells/ml and 1×10^5 cells/ml. 10 μ l of the cell suspension from each dilution was dispensed into 24 wells of a 96 well plate containing 2 μ l One-step RT-PCR enzyme (Qiagen), 10 μ l 5x One-step RT-PCR buffer (Qiagen), 10 μ l Triton-x100 (0.3%), 0.25 μ l RNasin (40U/ μ l), 2 μ l dNTPs (10 mM each), 1 μ l of tat 1.4 forward primer (20 μ M) and rev reverse primer (20 μ M) (as published in ⁸⁴), and nuclease free water to a final reaction volume of 50 μ l. The one-step RT-PCR was run using the following thermocycling conditions: 50°C for 30 minutes, 95°C for 15 minutes, 25 cycles of 95°C for 1 minute, 55°C for 1 min and 72°C for 2 minutes, and a final extension at 72°C for 5 minutes. Afterwards 2 μ l of the 1st PCR products were used as input for real time PCR to detect *tat/rev* msRNA. The 20 μ l reaction volume consisted of 5 μ l Taqman Fast Advanced Mastermix 4x (Thermo Fisher Scientific), 0.4 μ l of tat 2.0 forward primer and rev reverse primer (each at 20 μ M) and *tat/rev* probe (5 μ M) ⁸⁴. The real time PCR was performed in a LightCycler 480 Instrument II (Roche) using the following programme: 50°C for 5 minutes, 95°C for 20 seconds, 45 cycles of 95°C for 3 seconds and 60°C for 30 seconds. Positive wells at each dilution were recorded and used to determine the frequency of cells expressing *tat/rev* msRNA by maximum likelihood method using ELDA software ⁸⁵.

Statistical Analysis

969 All data are means $\pm$ SD of three or more independent biological replicates. Statistical significance
970 was calculated using two-tailed *t* test and indicated in Fig. legends. Analyses were performed using
971 Prism version 8.3.0 (GraphPad software).

972

973 REFERENCES

- 974 1 Finzi, D. *et al.* Identification of a reservoir for HIV-1 in patients on highly active antiretroviral
975 therapy. *Science* **278**, 1295-1300 (1997).
- 976 2 Chun, T. W., Moir, S. & Fauci, A. S. HIV reservoirs as obstacles and opportunities for an HIV
977 cure. *Nat Immunol* **16**, 584-589 (2015).
- 978 3 Deeks, S. G. HIV: Shock and kill. *Nature* **487**, 439-440 (2012).
- 979 4 Delagrèverie, H. M., Delaugerre, C., Lewin, S. R., Deeks, S. G. & Li, J. Z. Ongoing Clinical Trials
980 of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. *Open*
981 *Forum Infect Dis* **3**, ofw189-ofw189, doi:10.1093/ofid/ofw189 (2016).
- 982 5 Rasmussen, T. A. & Lewin, S. R. Shocking HIV out of hiding: where are we with clinical trials of
983 latency reversing agents? *Curr Opin HIV AIDS* **11**, 394-401 (2016).
- 984 6 Zerbato, J. M., Purves, H. V., Lewin, S. R. & Rasmussen, T. A. Between a shock and a hard place:
985 challenges and developments in HIV latency reversal. *Curr Opin Virol* **38**, 1-9 (2019).
- 986 7 Thorlund, K., Horwitz, M. S., Fife, B. T., Lester, R. & Cameron, D. W. Landscape review of current
987 HIV 'kick and kill' cure research - some kicking, not enough killing. *BMC Infect Dis* **17**, 595-595,
988 doi:10.1186/s12879-017-2683-3 (2017).
- 989 8 Leth, S. *et al.* Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-
990 stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm,
991 phase 1B/2A trial. *Lancet HIV* **3**, e463-472 (2016).
- 992 9 Fidler, S. *et al.* Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill
993 approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER
994 trial): a phase 2, randomised trial. *Lancet* **395**, 888-898 (2020).
- 995 10 Gay, C. L. *et al.* Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and
996 vorinostat on persistent HIV-1 Infection. *Sci Rep* **10**, 5134 (2020).
- 997 11 Margolis, D. M. *et al.* Curing HIV: Seeking to Target and Clear Persistent Infection. *Cell* (2020).
- 998 12 Cummins, N. W. & Badley, A. D. Mechanisms of HIV-associated lymphocyte apoptosis: 2010.
999 *Cell Death Dis* **1**, e99-e99, doi:10.1038/cddis.2010.77 (2010).
- 1000 13 Kim, Y., Anderson, J. L. & Lewin, S. R. Getting the "Kill" into "Shock and Kill": Strategies to
1001 Eliminate Latent HIV. *Cell Host Microbe* **23**, 14-26 (2018).
- 1002 14 Cooney, J., Allison, C., Preston, S. & Pellegrini, M. Therapeutic manipulation of host cell death
1003 pathways to facilitate clearance of persistent viral infections. *J Leukoc Biol* **103**, 287-293 (2018).
- 1004 15 Baxter, A. E. *et al.* Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-
1005 Infected Individuals. *Cell Host Microbe* **20**, 368-380 (2016).
- 1006 16 Grau-Exposito, J. *et al.* A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4(+)
1007 T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients. *mBio* **8** (2017).
- 1008 17 Berg, R. K. *et al.* Genomic HIV RNA induces innate immune responses through RIG-I-dependent
1009 sensing of secondary-structured RNA. *PLoS One* **7**, e29291 (2012).
- 1010 18 Fong, L. E., Sulistijo, E. S. & Miller-Jensen, K. Systems analysis of latent HIV reversal reveals
1011 altered stress kinase signaling and increased cell death in infected T cells. *Sci Rep* **7**, 16179-16179,
1012 doi:10.1038/s41598-017-15532-0 (2017).
- 1013 19 Baxter, A. E., O'Doherty, U. & Kaufmann, D. E. Beyond the replication-competent HIV reservoir:
1014 transcription and translation-competent reservoirs. *Retrovirology* **15**, 18 (2018).
- 1015 20 Baxter, A. E. *et al.* Multiparametric characterization of rare HIV-infected cells using an RNA-flow
1016 FISH technique. *Nat Protoc* **12**, 2029-2049 (2017).
- 1017 21 Rao, S., Amorim, R., Niu, M., Temzi, A. & Mouland, A. J. The RNA surveillance proteins UPF1,
1018 UPF2 and SMG6 affect HIV-1 reactivation at a post-transcriptional level. *Retrovirology* **15**, 42
1019 (2018).

1020 22 Grau-Expósito, J. *et al.* Latency reversal agents affect differently the latent reservoir present in
1021 distinct CD4+ T subpopulations. *PLoS Pathog* **15**, e1007991 (2019).
1022 23 Linder, P. & Jankowsky, E. From unwinding to clamping — the DEAD box RNA helicase family.
1023 *Nature Reviews Molecular Cell Biology* **12**, 505-516, doi:10.1038/nrm3154 (2011).
1024 24 Zhao, L. *et al.* Multifunctional DDX3: dual roles in various cancer development and its related
1025 signaling pathways. *Am J Cancer Res* **6**, 387-402 (2016).
1026 25 Soto-Rifo, R. & Ohlmann, T. The role of the DEAD-box RNA helicase DDX3 in mRNA
1027 metabolism. *Wiley Interdiscip Rev RNA* **4**, 369-385 (2013).
1028 26 Lin, T. C. DDX3X Multifunctionally Modulates Tumor Progression and Serves as a Prognostic
1029 Indicator to Predict Cancer Outcomes. *Int J Mol Sci* **21** (2019).
1030 27 Bol, G. M., Xie, M. & Raman, V. DDX3, a potential target for cancer treatment. *Mol Cancer* **14**,
1031 188 (2015).
1032 28 Heerma van Voss, M. R., van Diest, P. J. & Raman, V. Targeting RNA helicases in cancer: The
1033 translation trap. *Biochim Biophys Acta Rev Cancer* **1868**, 510-520 (2017).
1034 29 He, Y. *et al.* A double-edged function of DDX3, as an oncogene or tumor suppressor, in cancer
1035 progression (Review). *Oncol Rep* **39**, 883-892 (2018).
1036 30 Kukhanova, M. K., Karpenko, I. L. & Ivanov, A. V. DEAD-box RNA Helicase DDX3: Functional
1037 Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs. *Molecules* **25**
1038 (2020).
1039 31 Valiente-Echeverria, F., Hermoso, M. A. & Soto-Rifo, R. RNA helicase DDX3: at the crossroad
1040 of viral replication and antiviral immunity. *Rev Med Virol* **25**, 286-299 (2015).
1041 32 Yedavalli, V. S., Neuveut, C., Chi, Y. H., Kleiman, L. & Jeang, K. T. Requirement of DDX3 DEAD
1042 box RNA helicase for HIV-1 Rev-RRE export function. *Cell* **119**, 381-392 (2004).
1043 33 Mahboobi, S. H., Javanpour, A. A. & Mofrad, M. R. The interaction of RNA helicase DDX3 with
1044 HIV-1 Rev-CRM1-RanGTP complex during the HIV replication cycle. *PLoS One* **10**, e0112969
1045 (2015).
1046 34 Soto-Rifo, R. *et al.* DEAD-box protein DDX3 associates with eIF4F to promote translation of
1047 selected mRNAs. *Embo J* **31**, 3745-3756 (2012).
1048 35 Frohlich, A. *et al.* DEAD-box RNA helicase DDX3 connects CRM1-dependent nuclear export and
1049 translation of the HIV-1 unspliced mRNA through its N-terminal domain. *Biochim Biophys Acta*
1050 **1859**, 719-730 (2016).
1051 36 Soto-Rifo, R., Rubilar, P. S. & Ohlmann, T. The DEAD-box helicase DDX3 substitutes for the
1052 cap-binding protein eIF4E to promote compartmentalized translation initiation of the HIV-1
1053 genomic RNA. *Nucleic Acids Res* **41**, 6286-6299 (2013).
1054 37 Gringhuis, S. I. *et al.* Erratum: HIV-1 blocks the signaling adaptor MAVS to evade antiviral host
1055 defense after sensing of abortive HIV-1 RNA by the host helicase DDX3. *Nat Immunol* **18**, 474
1056 (2017).
1057 38 Brai, A. *et al.* Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents.
1058 *Proc Natl Acad Sci U S A* **113**, 5388-5393 (2016).
1059 39 Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection after acute
1060 infection of T cells in vitro. *Embo J* **22**, 1868-1877 (2003).
1061 40 Bol, G. M. *et al.* Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. *EMBO*
1062 *Mol Med* **7**, 648-669 (2015).
1063 41 Kondaskar, A. *et al.* Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-
1064 Fused Diimidazodiazepine Ring System. *ACS Med Chem Lett* **2**, 252-256 (2010).
1065 42 Heerma van Voss, M. R. *et al.* Identification of the DEAD box RNA helicase DDX3 as a
1066 therapeutic target in colorectal cancer. *Oncotarget* **6**, 28312-28326 (2015).
1067 43 Xie, M. *et al.* RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.
1068 *Cancer Res* **76**, 6340-6350 (2016).
1069 44 Heerma van Voss, M. R. *et al.* Targeting mitochondrial translation by inhibiting DDX3: a novel
1070 radiosensitization strategy for cancer treatment. *Oncogene* **37**, 63-74 (2018).

1071 45 Wang, X. *et al.* (DEAD)-box RNA helicase 3 modulates NF-kappaB signal pathway by controlling
1072 the phosphorylation of PP2A-C subunit. *Oncotarget* **8**, 33197-33213 (2017).

1073 46 Xiang, N. *et al.* The DEAD-Box RNA Helicase DDX3 Interacts with NF-kB Subunit p65 and
1074 Suppresses p65-Mediated Transcription. *PloS one* **11**, e0164471-e0164471,
1075 doi:10.1371/journal.pone.0164471 (2016).

1076 47 Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. *Cell* **124**, 783-
1077 801 (2006).

1078 48 Yoneyama, M. & Fujita, T. RNA recognition and signal transduction by RIG-I-like receptors.
1079 *Immunol Rev* **227**, 54-65 (2009).

1080 49 Hiscott, J. Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral
1081 response. *Cytokine Growth Factor Rev* **18**, 483-490 (2007).

1082 50 Balachandran, S. *et al.* Alpha/beta interferons potentiate virus-induced apoptosis through activation
1083 of the FADD/Caspase-8 death signaling pathway. *J Virol* **74**, 1513-1523 (2000).

1084 51 Chawla-Sarkar, M. *et al.* Apoptosis and interferons: Role of interferon-stimulated genes as
1085 mediators of apoptosis. *Apoptosis* **8**, 237-249, doi:10.1023/a:1023668705040 (2003).

1086 52 Juang, S. H. *et al.* IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in
1087 human advanced stage colon cancer cell lines. *J Interferon Cytokine Res* **24**, 231-243 (2004).

1088 53 Radi, M. *et al.* Discovery of the first small molecule inhibitor of human DDX3 specifically
1089 designed to target the RNA binding site: towards the next generation HIV-1 inhibitors. *Bioorg Med*
1090 *Chem Lett* **22**, 2094-2098 (2012).

1091 54 Kuo, H. H. *et al.* Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4(+) T
1092 Cells. *Immunity* **48**, 1183-1194 e1185 (2018).

1093 55 Iordanskiy, S. *et al.* Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced
1094 by human immunodeficiency virus type 1 viral protein R. *J Virol* **78**, 9697-9704,
1095 doi:10.1128/jvi.78.18.9697-9704.2004 (2004).

1096 56 Kumar, M. *et al.* Reciprocal regulation of human immunodeficiency virus-1 gene expression and
1097 replication by heat shock proteins 40 and 70. *J Mol Biol* **410**, 944-958 (2011).

1098 57 Chaudhary, P. *et al.* HSP70 binding protein 1 (HspBP1) suppresses HIV-1 replication by inhibiting
1099 NF-kB mediated activation of viral gene expression. *Nucleic acids research* **44**, 1613-1629,
1100 doi:10.1093/nar/gkv1151 (2016).

1101 58 Lassen, K. G., Hebbeler, A. M., Bhattacharyya, D., Lobritz, M. A. & Greene, W. C. A flexible
1102 model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. *PloS one* **7**,
1103 e30176-e30176, doi:10.1371/journal.pone.0030176 (2012).

1104 59 Stoszko, M. *et al.* Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-
1105 1 Latency Reversal. *EBioMedicine* **3**, 108-121, doi:10.1016/j.ebiom.2015.11.047 (2015).

1106 60 Marian, C. A. *et al.* Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV
1107 Latency Reversal. *Cell Chem Biol* **25**, 1443-1455 e1414 (2018).

1108 61 Nakahara, T. *et al.* YM155, a novel small-molecule survivin suppressant, induces regression of
1109 established human hormone-refractory prostate tumor xenografts. *Cancer Res* **67**, 8014-8021
1110 (2007).

1111 62 Pache, L. *et al.* BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted
1112 by Smac Mimetics to Promote Reversal of Viral Latency. *Cell Host Microbe* **18**, 345-353 (2015).

1113 63 Nixon, C. C. *et al.* Systemic HIV and SIV latency reversal via non-canonical NF-kappaB signalling
1114 in vivo. *Nature* **578**, 160-165 (2020).

1115 64 Bobardt, M. *et al.* The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1
1116 latency reversal candidate. *PLoS One* **14**, e0211746 (2019).

1117 65 Matsuda, K. *et al.* Benzolactam-related compounds promote apoptosis of HIV-infected human cells
1118 via protein kinase C-induced HIV latency reversal. *J Biol Chem* **294**, 116-129,
1119 doi:10.1074/jbc.RA118.005798 (2019).

1120 66 Hattori, S. I. *et al.* Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes
1121 Secondary HIV-1 Infection in vitro. *Front Microbiol* **9**, 2022 (2018).

1122 67 Rosás-Umbert, M. *et al.* In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and
1123 Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. *Frontiers in Immunology* **11**,
1124 doi:10.3389/fimmu.2020.00418 (2020).

1125 68 Brai, A. *et al.* DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host
1126 proteins. *Eur J Med Chem* **200**, 112319 (2020).

1127 69 Cummins, N. W. *et al.* Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2
1128 Inhibition. *J Virol* **91**, e00012-00017, doi:10.1128/jvi.00012-17 (2017).

1129 70 Chandrasekar, A. P., Cummins, N. W. & Badley, A. D. The Role of the BCL-2 Family of Proteins
1130 in HIV-1 Pathogenesis and Persistence. *Clin Microbiol Rev* **33** (2019).

1131 71 Campbell, G. R., Bruckman, R. S., Chu, Y. L., Trout, R. N. & Spector, S. A. SMAC Mimetics
1132 Induce Autophagy-Dependent Apoptosis of HIV-1-Infected Resting Memory CD4+ T Cells. *Cell*
1133 *Host Microbe* **24**, 689-702 e687 (2018).

1134 72 Zhang, G. *et al.* Selective cell death of latently HIV-infected CD4(+) T cells mediated by autosis
1135 inducing nanopeptides. *Cell Death Dis* **10**, 419 (2019).

1136 73 Lucas, A. *et al.* Targeting the PI3K/Akt Cell Survival Pathway to Induce Cell Death of HIV-1
1137 Infected Macrophages with Alkylphospholipid Compounds. *PLOS ONE* **5**, e13121 (2010).

1138 74 Tateishi, H. *et al.* A clue to unprecedented strategy to HIV eradication: "Lock-in and apoptosis".
1139 *Sci Rep* **7**, 8957-8957, doi:10.1038/s41598-017-09129-w (2017).

1140 75 Stoszko, M. *et al.* Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP,
1141 releases P-TEFb and reverses HIV-1 latency. *bioRxiv*, 848929, doi:10.1101/848929 (2019).

1142 76 Stoszko, M., Ne, E., Abner, E. & Mahmoudi, T. A broad drug arsenal to attack a strenuous latent
1143 HIV reservoir. *Current Opinion in Virology* **38**, 37-53,
1144 doi:https://doi.org/10.1016/j.coviro.2019.06.001 (2019).

1145 77 Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method.
1146 *Nat Protoc* **3**, 1101-1108 (2008).

1147 78 Naldini, L., Blömer, U., Gage, F. H., Trono, D. & Verma, I. M. Efficient transfer, integration, and
1148 sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.
1149 *Proceedings of the National Academy of Sciences* **93**, 11382, doi:10.1073/pnas.93.21.11382
1150 (1996).

1151 79 Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory research and analysis.
1152 *J Comput Chem* **25**, 1605-1612 (2004).

1153 80 Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new
1154 scoring function, efficient optimization, and multithreading. *J Comput Chem* **31**, 455-461 (2010).

1155 81 Schmidt, E. K., Clavarino, G., Ceppi, M. & Pierre, P. SUnSET, a nonradioactive method to monitor
1156 protein synthesis. *Nature Methods* **6**, 275-277, doi:10.1038/nmeth.1314 (2009).

1157 82 Pasternak, A. O. *et al.* Highly Sensitive Methods Based on Seminested Real-Time Reverse
1158 Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 Unspliced and
1159 Multiply Spliced RNA and Proviral DNA. *Journal of Clinical Microbiology* **46**, 2206,
1160 doi:10.1128/jcm.00055-08 (2008).

1161 83 Lungu, C. *et al.* Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by
1162 TILDA. *Viruses* **12** (2020).

1163 84 Procopio, F. A. *et al.* A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in
1164 HIV-infected Individuals. *EBioMedicine* **2**, 874-883 (2015).

1165 85 Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and
1166 enriched populations in stem cell and other assays. *J Immunol Methods* **347**, 70-78 (2009).

1167

1168

ACKNOWLEDGEMENTS

We would like to thank Jan-Willem Bakker, Alessia Tarditi and Matteo Andreini from First Health Pharmaceuticals Amsterdam for generous provision of the DDX3 inhibitor FH-1321; and Tsung Wai Kan for technical help.

FUNDING

The research leading to these results has received funding from the Dutch AIDS Fonds (grants P-53302 and P-53601), Health Holland (grants LSHM19100-SGF and EMCLSH19023), ZonMW (grant 40-44600-98-333), the Federation of Medical Specialists (grant 59825822) and the EHVA T01 consortium, which is supported by the European Union's Horizon 2020 Research and Innovation Programme (grant 681032).

AUTHOR CONTRIBUTIONS

S.R. and T.M designed the studies; S.R., C.L., T.H.S., R.C. and A.G. conducted experiments and performed data analysis; S.R., R.J.P. and W.V.I participated in gene expression analysis; H.P., C.R. and A.V. recruited patients for the study; Y.M.M., P.D.K., J.V.K., C.B., R.G. and T.M. provided expertise and supervision; S.R. and T.M. wrote the manuscript with input from all authors. All authors read and approved the final manuscript.

1188 **COMPETING INTERESTS**

1189 The authors declare that they have no competing interests.

1190

1191 **DATA AND MATERIALS AVAILABILITY**

1192 All data needed to evaluate the conclusions in the paper are present in the paper and/or the
1193 Supplementary Materials. Additional data related to this paper may be requested from the authors.

1194

1195

1196 **Table 1: EdgeR report of differentially expressed genes 18h post treatment with 2 μ M RK-33**

GeneID	Name	log2 Fold Change	log2 Counts Per Million	F Value	P Value	False Discovery Rate
ENSG00000133124	IRS4	-9.220240267	1.229125796	149.1749	2.89E-34	1.69E-29
ENSG00000096696	DSP	-8.484792295	0.549901848	93.17747	4.97E-22	9.65E-18
ENSG00000145147	SLIT2	-8.122797551	0.215628794	69.49186	7.84E-17	1.14E-12
ENSG00000261409	AL035425.3	-8.022265953	0.113605342	60.57704	7.19E-15	5.99E-11
ENSG00000138829	FBN2	-7.721874417	-0.141878891	49.16692	2.38E-12	1.39E-08
ENSG00000083857	FAT1	-7.711916601	-0.142206665	50.58668	1.15E-12	7.47E-09
ENSG00000154277	UCHL1	-7.629659662	-0.220071849	45.5358	1.51E-11	7.35E-08
ENSG00000139219	COL2A1	-7.594048405	-0.247211954	44.80238	2.20E-11	9.86E-08
ENSG00000229807	XIST	-7.425086724	4.779411144	281.6285	8.79E-06	0.013432
ENSG00000089685	BIRC5	-7.372112695	-0.421255852	38.53409	5.42E-10	2.26E-06
ENSG00000116962	NID1	-7.05272162	-0.69051715	28.24878	1.07E-07	0.000297
ENSG00000038427	VCAN	-7.017959819	-0.727725687	25.70546	3.99E-07	0.000861
ENSG00000176887	SOX11	-7.004754934	-0.728056321	27.13324	1.91E-07	0.000483
ENSG00000117114	ADGRL2	-6.95027203	-0.766705238	26.38183	2.81E-07	0.000655
ENSG00000054598	FOXC1	-6.756514098	-0.931471077	19.71939	8.99E-06	0.013432
ENSG00000188153	COL4A5	-6.756514098	-0.931471077	19.71939	8.99E-06	0.013432
ENSG00000197565	COL4A6	-6.610183248	-1.02235097	19.90055	8.17E-06	0.013236
ENSG00000169855	ROBO1	-6.551036428	-1.069611081	18.62718	1.59E-05	0.021095
ENSG00000170558	CDH2	-6.544969004	-1.069721671	18.90017	1.38E-05	0.019153
ENSG00000159217	IGF2BP1	-5.889308666	0.348421941	64.80318	8.72E-16	1.02E-11
ENSG00000135862	LAMC1	-5.486512767	0.002490741	48.29217	3.71E-12	1.97E-08
ENSG00000102024	PLS3	-4.323906265	1.49827749	117.2158	3.02E-27	8.81E-23
ENSG00000171246	NPTX1	-3.992292706	-0.550303193	23.25519	1.42E-06	0.002675
ENSG00000154734	ADAMTS1	-3.971030294	0.580596315	60.82655	6.34E-15	5.99E-11
ENSG00000145555	MYO10	-3.696600515	-0.303481708	26.65852	2.44E-07	0.000592
ENSG00000154380	ENAH	-3.64365296	-0.274861002	25.06365	5.59E-07	0.001124
ENSG00000142949	PTPRF	-3.553235332	-0.021528142	33.79895	6.35E-09	1.95E-05
ENSG00000163430	FSTL1	-3.20753747	-0.332407149	22.31002	2.33E-06	0.003987
ENSG00000117399	CDC20	-3.098292124	-0.420984699	17.47004	2.92E-05	0.034778

ENSG00000176788	BASP1	-3.03195077	-0.24810378	22.38461	2.24E-06	0.003952
ENSG00000111206	FOXMI	-3.015861999	0.001271235	28.7242	8.38E-08	0.000244
ENSG00000046604	DSG2	-2.684610226	0.484772447	34.90713	3.48E-09	1.19E-05
ENSG00000101057	MYBL2	-2.316037106	0.025267442	17.38763	3.06E-05	0.035688
ENSG00000148773	MKI67	-1.384356143	1.091562301	18.66531	1.56E-05	0.021095
ENSG00000083444	PLOD1	-1.18441556	1.399169378	17.50631	2.88E-05	0.034778
ENSG00000131747	TOP2A	-1.054906153	1.866051914	19.13111	1.25E-05	0.017772
ENSG00000204388	HSPA1B	-0.741213605	3.325135537	27.77549	1.39E-07	0.000367
ENSG00000178429	RPS3AP5	2.015230135	1.279297836	36.33718	3.41E-09	1.19E-05
ENSG00000234648	AL162151.2	4.827847593	0.344327701	50.73859	1.07E-12	7.47E-09

1197

1198

1199 **Table 2: EdgeR report of differentially expressed genes 18h post treatment with 1μM FH-**

1200 **1321**

GeneID	Name	log2 Fold Change	log2 Counts Per Million	F value	PValue	False Discovery Rate
ENSG00000154277	UCHL1	-4.565471687	-0.206793672	38.67266739	5.05E-10	3.31E-06
ENSG00000261409	AL035425.3	-4.424650789	0.138068277	48.33716477	3.63E-12	3.52E-08
ENSG00000138829	FBN2	-4.131894042	-0.10684436	38.38083941	5.86E-10	3.42E-06
ENSG00000116962	NID1	-3.999181717	-0.658930046	22.77369298	1.83E-06	0.0053254
ENSG00000117114	ADGRL2	-3.832053102	-0.731611642	20.4765316	6.05E-06	0.0125945
ENSG00000159217	IGF2BP1	-3.68912559	0.398606752	48.96044087	2.64E-12	3.08E-08
ENSG00000229807	XIST	-3.488985213	4.901654584	651.1533715	7.66E-143	4.47E-138
ENSG00000038427	VCAN	-3.429296401	-0.658534387	18.19677341	2.00E-05	0.0323138
ENSG00000154734	ADAMTS1	-3.363272907	0.603352768	54.52344803	1.56E-13	2.27E-09
ENSG00000212402	SNORA74B	-3.359506375	0.031288549	24.79248338	5.34E-06	0.0115336
ENSG00000145147	SLIT2	-3.051459541	0.34517457	38.64546164	5.12E-10	3.31E-06
ENSG00000101057	MYBL2	-2.996889004	-0.083099003	26.07056348	3.34E-07	0.0010805
ENSG00000133124	IRS4	-2.98565677	1.371029055	71.98000489	2.22E-17	6.48E-13
ENSG00000083857	FAT1	-2.913815462	-0.014539277	28.05815995	1.18E-07	0.0004052
ENSG00000145555	MYO10	-2.805586002	-0.261404374	22.18212809	2.49E-06	0.0066275
ENSG00000139219	COL2A1	-2.783583292	-0.107869982	24.02115361	9.55E-07	0.0029316
ENSG00000201098	RNY1	-2.770572459	0.413772602	35.10682622	4.80E-09	2.33E-05
ENSG00000135862	LAMC1	-2.712320987	0.135877854	28.32916412	1.03E-07	0.0003743
ENSG00000102024	PLS3	-2.681318527	1.605768497	71.57130553	3.77E-17	7.32E-13
ENSG00000096696	DSP	-2.636756013	0.730407853	42.41260665	7.45E-11	6.21E-07
ENSG00000089685	BIRC5	-2.490957592	-0.234929297	18.96212263	1.34E-05	0.02512
ENSG00000238741	SCARNA7	-2.387719434	0.361869871	24.20859794	2.61E-06	0.0066275
ENSG00000163430	FSTL1	-2.380561336	-0.26218126	17.71426598	2.57E-05	0.0405086
ENSG00000200785	SNORD8	-2.299517907	-0.084333496	18.58796384	1.64E-05	0.0290541
ENSG00000142949	PTPRF	-2.256619192	0.113519171	22.13114508	2.55E-06	0.0066275
ENSG00000111206	FOXMI	-2.226389714	0.092218251	21.57249486	3.41E-06	0.0082946
ENSG00000212283	SNORD89	-1.860714666	1.311190667	36.42603494	1.90E-09	1.01E-05

ENSG00000208772	SNORD94	-1.822933237	1.022233292	29.05095049	7.20E-08	0.0002797
ENSG00000166165	CKB	-1.686278111	1.500619457	33.19463106	9.30E-09	4.17E-05
ENSG00000046604	DSG2	-1.609604699	0.644434181	18.28993873	1.90E-05	0.031651
ENSG00000202058	RN7SKP80	-1.234932643	1.641387087	21.21111392	4.96E-06	0.011119
ENSG00000126016	AMOT	-0.773124251	3.662624092	30.45093151	3.53E-08	0.0001469
ENSG00000130164	LDLR	-0.411325614	5.764550633	21.07423587	4.43E-06	0.0103253
ENSG00000101745	ANKRD12	0.339396244	7.502647544	18.65815618	1.57E-05	0.0285379
ENSG00000170881	RNF139	0.423776234	5.074578288	18.46989874	1.74E-05	0.0297963
ENSG00000213757	AC020898.1	0.876931574	2.474353677	19.06819338	1.27E-05	0.0246334
ENSG00000198064	NPIP13	2.365643737	0.043629688	19.87731825	8.31E-06	0.0167005

1201

1202

Table 3: Characteristics of PLWHIV donors used in this study

Colour code	Sex	Age	Time from HIV-1 diagnosis to Leukapheresis	Time on ART at leukapheresis	Time with continuous HIV-1 RNA <50 copies/ml
Donor 1	Male	66	52 months	52 months	48 months
Donor 2	Male	75	108 months	81 months	75 months
Donor 3	Male	47	85 months	72 months	64 months
Donor 4	Male	67	86 months	86 months	12 months
Donor 5	Female	42	55 months	55 months	52 months
Donor 6	Male	50	124 months	49 months	48 months
Donor 7	Male	35	19 months	19 months	17 months
Donor 8	Male	42	77 months	77 months	71 months
Donor 9	Male	57	18 months	17 months	2 months
Donor 10	Male	50	100 months	42 months	37 months

Table 4: List of primers used in this study

Target gene:	Forward:	Reverse:
GFP	5'-GAAGCAGCACGACTTCTTCAA-3'	5'-GCTTGTCGGCCATGATATAGA-3'
Pol	5'-GGTTTATTACAGGGACAGCAGAGA-3'	5'-ACCTGCCATCTGTTTTCCATA-3'
MMP9	5'-TGGTCCTGGTGCCTGGTG-3'	5'-GCTGCCTGTCGGTGAGATTGG-3'
BCL2	5'-GGTGGGGTCATGTGTGTGG -3'	5'-CGGTTCAAGGTACTCAGTCATCC-3'
Bax	5'-CCCGAGAGGTCTTTTCCGAG -3'	5'-CCAGCCCATGATGGTTCTGAT -3'
IL10	5'-CATCGATTCTTCCCTGTGAA-3'	5'-TCTTGGAGCTTATTAAAGGCATTC-3'
GAPDH	5'-CAAGAAGGTGGTGAAGCAG-3'	5'-GCCAAATTCGTTGTCATACC-3'
RIG-I	5'-CCAAGCCAAAGCAGTTTTCAAG -3'	5'-CATGGATTCCCCAGTCATGG-3'
MAVS	5'-TGATTTCCTCGCAATCAGACG -3'	5'-GAAGCCGATTCCAGCTGTATG-3'
BIRC5	5'-CAAGGACCACCGCATCTCTAC-3'	5'-AGTCTGGCTCGTTCTCAGTGG-3'
HSPA1B	5'-ACCTTCGACGTGTCCATCCTGA -3'	5'-TCCTCCACGAAGTGGTTCACCA -3'
IL8	5'-CTCTCTTGGCAGCCTTCC -3'	5'-TCCACTCTCAATCACTCTCAG-3'
Cyclophilin A	5'-TCATCTGCACTGCCAAGACTG-3'	5'-CATGCCTTCTTTCACTTTGCC-3'
DDX3X	5'-GGAGGAAGTACAGCCAGCAAAG-3'	5'-CTGCCAATGCCATCGTAATCACTC-3'
MS RNA	5'-GACTCATCAAGTTTCTCTATC AAA-3'	5'-AGTCTCTCAAGCGGTGGT-3'